FDA Approves AstraZenecas Farxiga for Heart Failure in Adults with Reduced Ejection Fraction

The U.S. Food and Drug Administration (FDA) announced on Tuesday that it has approved dapagliflozin, also known under the brand name Farxiga, for the treatment of heart failure in adults with reduced ejection fraction. The drug can potentially reduce the risk of cardiovascular death and hospitalization for heart failure.

AstraZenecas Farxiga is now the first in its drug class of sodium-glucose co-transporter 2 (SGLT2) inhibitors to be approved to treat adults with the New York Heart Associations functional class II-IV heart failure with reduced ejection fraction. AstraZeneca was granted with the approval of Farxiga related to heart failure by the FDA.

In a clinical trial, Farxiga appeared to improve survival and reduce the need for hospitalization in adults with heart failure and reduced ejection fraction.

To determine the efficacy of the drug, researchers looked at the number of instances of cardiovascular death, hospitalization for heart failure and urgent heart failure visits. Some trial participants were given a once-daily dose of 10mg of Farxiga, while others were given a placebo. After approximately 18 months, those who were given Farxiga had fewer cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits compared to their counterparts.

Heart failure is a serious health condition that contributes to one in eight deaths in the U.S. and impacts nearly 6.5 million Americans, said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiology and Nephrology in the FDAs Center for Drug Evaluation and Research. This approval provides patients with heart failure with reduced ejection fraction an additional treatment option that can improve survival and reduce the need for hospitalization.

Farxiga can cause side effects including dehydration, urinary tract infections and genetical yeast infections. It can also potentially result in serious cases of necrotizing fasciitis of the perineum in people with diabetes and low blood sugar when combined with insulin.

On Tuesday, BioCardia, Inc. also announced positive preclinical datasupporting its new drug application for anti-inflammatory cell therapy for heart failure. BioCardias allogenic neurokinin 1 receptor positive mesenchymal stem cell (NK1R+ MSC) therapy appeared to improve heart function in a study. NK1R+ MSC is being marketed under the name CardiALLO.

Alexanderstock23 / Shutterstock

Researchers looked at 26 animals treated with both low dose and high dose CardiALLO in their study. Echocardiographic measures of cardiac ejection fraction, fractional shortening and cardiac outflow all notably improved in the animals.

In light of these positive data on our allogenic NK1R+ MSC therapy, we expect to meet our internal timeline to complete our submission to the FDA for our first indication for CardiALLO, and potentially receive IND acceptance by the end of the second quarter, said BioCardia Chief Scientific Officer Ian McNiece, PhD. The MSCs that were studied are subtypes of MSC that we have delivered previously in our co-sponsored trials, which we believe have enhanced potency over MSC generated from unselected bone marrow cells. We look forward to seeing additional data from this animal study that are currently being analyzed, including histology and pathology of the heart and lungs.

BioCardia also intends to submit an IND for the use of NK1R+ MSC delivered via intravenous infusion for the treatment of Acute Respiratory Distress Syndrome caused by COVID-19.

Approximately 6.5 million adults in the U.S. are living with heart failure, according to the Centers for Disease Control and Protection. In 2017, it was a contributing cause of death in one out of eight people.

Go here to see the original:
FDA Approves AstraZeneca's Farxiga for Heart Failure in Adults with Reduced Ejection Fraction - PharmaLive

Recommendation and review posted by Bethany Smith

The global Cell Therapy Manufacturing Market research report thoroughly explains each and every aspect related to the Cell Therapy Manufacturing Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business. The growth trend forecasted on account of thorough examination offers in-depth information regarding the global Cell Therapy Manufacturing Market. A pathway of development is offered by the market to the several connected networks of businesses under it, which include different firms, industries, organizations, vendors, distributors, and local manufacturers too. All the key Cell Therapy Manufacturing Market players compete with each other by offering better products and services at a reasonable price in order to grab significant share at the regional and global level market.

Cell therapy is one of the most promising healthcare procedure for restoration of damaged tissue. Cell therapies have huge potential for the wide range of disease treatment including tissue degradation, immune deficiency, metabolic disorders, and cancer. Cell therapy are categorized into two types allogeneic (cells from third party donor) and autologous (cells from ones own body). Cell therapy has gained significant traction in recent past and currently it under commercial development. Main objective of cell therapy is to re-establish the lost function of tissues and cells rather than to produce a new organ. Some cell therapies have been established and permitted for clinical trial. For instance, in 2013 a stage 2 clinical trial was completed for transplantation of bone marrow derived stem cells in affected knee by rheumatoid arthritis. The growth of this technique is also increased due to involvement of the government agencies. For instance, innovate U.K. 2014 report showed that government agreed to fund US$15.3 million in cell therapy manufacturing market.ription

Get a Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/1728

This report sample includesBrief Introduction to the research report.Table of Contents (Scope covered as a part of the study)Top players in the marketResearch framework (presentation)Research methodology adopted by Coherent Market Insights

The report incorporates an estimated impact of strict standards and regulations set by the government over the market in the upcoming years. The market report also comprises exhaustive research done using several analytical tools such as SWOT analysis to identify the market growth pattern.

Top Manufacturers in GlobalCell Therapy ManufacturingMarket Includes:Pharmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

Regions & Countries Mentioned In The Cell Therapy Manufacturing Market Report:

North America ( United States)

Europe ( Germany, France, UK)

Asia-Pacific ( China, Japan, India)

Latin America ( Brazil)

The Middle East & Africa

Key Highlights of the Table of Contents:

Cell Therapy Manufacturing Market Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global market, years considered, and study objectives. Furthermore, it tuches the segmentation study provided in the report on the basis of the type of product and applications.

Cell Therapy Manufacturing Market Executive Summary: This section emphasizes on the key studies, market growth rate,Competitive landscape, market drivers, trends, and issues.

Cell Therapy Manufacturing Market Production by Region: The report provides information related to import and export, production, revenue, and key players of all regional markets studied are covered in this section.

Cell Therapy Manufacturing Market Profile of Manufacturers: Analysis of each market player profiled is detailed in this section. This also provides SWOT analysis, products, production, value, capacity, and other vital factors of the individual player.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/1728

Table of Contents

Report Overview:It includes the Cell Therapy Manufacturing market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about Cell Therapy Manufacturing market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the Cell Therapy Manufacturing market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the Cell Therapy Manufacturing market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Get Download PDF Brochure https://www.coherentmarketinsights.com/insight/request-pdf/1728

About CMI:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Coherent Market Insights 1001 4th Ave,#3200 Seattle, WA 98154,U.SPhone: US +12067016702 / UK +4402081334027Email: [emailprotected]

Read more:
Cell Therapy Manufacturing Market 2020 Coronavirus (Covid-19) Business Impact Size Will Escalate Rapidly in the Near Future 3w Market News Reports -...

Recommendation and review posted by Bethany Smith

Laila Anderson continues to make an impact in the lives of others one year after she became part of the Blues run to the 2019 Stanley Cup title.

On Tuesday, Anderson, who has battled HLH, a disease that causes the body to make too many immune cells, took part in an all-day livestream event called Couch2Cure to benefit Be the Match. It served as not only a fundraiser, but also a call for people to become donors for patients seeking blood stem cell matches. She was joined by FOX play-by-play man Joe Buck and Blues PA announcer Tom Calhoun.

The event was a success, raising$1.45 million and resulting in 36,000 registries to the Be the Match program.

Laila spoke with NBC Sports Kathryn Tappen on Wednesday to talk about the Couch2Cure event, the importance of the Be the Match registry, and how shes doing one year after the Blues triumph.

MORE LAILA ANDERSON: Laila introduces Blues All-Stars with gusto Blues superfan enjoying life one year after bone marrow transplant Laila meets bone marrow donor Laila gets moment with Stanley Cup

Sean Leahy is a writer for Pro Hockey Talk on NBC Sports. Drop him a line at phtblog@nbcsports.com or follow him on Twitter @Sean_Leahy.

British Columbia Premier John Horgan has offered the NHL a place to play if the league can find a way to resume the season.

Speaking at a COVID-19 media briefing Wednesday, Horgan said he has written a letter to both NHL Commissioner Gary Bettman and NHL Players Association head Donald Fehr to let them know B.C. is a place to potentially restart the NHL assuming the games would be played without audiences, but instead played for television.

The NHL suspended its season March 12 with 189 regular-season games left.

Dr. Bonnie Henry, British Columbias provincial health officer, was asked Monday about Vancouver hosting NHL games with no fans and said: These are the types of things that we need to think about.

Ontario Premier Doug Ford said Tuesday the Maple Leafs parent company, MLSE, has been in contact with the province about the possibility of Toronto serving as a hockey pod for teams as well. Alberta Premier Jason Kenney and Bettman spoke last month about Edmonton as another potential hub city.

Welcome to the PHT Morning Skate, a collection of links from around the hockey world. Have a link you want to submit? Email us atphtblog@nbcsports.com.

A really nice read about ex-Blackhawks president John McDonoughs friendship with 11-year-old Cammy Babiarz, who is unable to walk or talk because of Rett Syndrome a rare developmental disorder. [Midway Minute]

It didnt last very long, but at one point in time Michael Jordan was a minority owner of the Capitals. [ESPN]

Economies are beginning to open up again, so too are hockey rinks in the U.S. [The Hockey News]

Georges Laraque opens about his up and down relationship with his father. [Vice]

How the 2011-12 Kings became unlikely Stanley Cup champions. [The Score]

Comparing Brady Tkachuks early days in the NHL to that of Mark Stones. [Silver Seven Sens]

What if some of NHLs all-time best hadnt run into historic dynasties? [Sportsnet]

Looking ahead to whats expected to be an intriguing 2022 NHL draft class. [Stephen Ellis]

Finally, the Wild music video you were looking for:

Sean Leahy is a writer for Pro Hockey Talk on NBC Sports. Drop him a line at phtblog@nbcsports.com or follow him on Twitter @Sean_Leahy.

After pulling the plug on the 2019-20 season in March, the KHL has decided there will be no champion and the Gagarin Cup will not be awarded for the first time in league history.

Due to this decision, the league has equally ranked the eight teams that advanced to the second round of the playoffs:Ak Bars Kazan,Barys Nur-Sultan,CSKA Moscow,Dynamo Moscow,Jokerit Helsinki,Salavat Yulaev Ufa,Sibir Novosibirsk, and SKA St. Petersburg.

From the KHL:

With the season incomplete, there is no way that a Gagarin Cup winner and other prize winners can be fairly chosen based on the results of the regular season. To announce a champion based on the regular season and one round of the playoffs would violate the sporting integrity of the competition.

The Russian Hockey Federation has drawn up a separate procedure to determine the Russian Champion for the 2019-20 season, and to award silver and bronze medals to the second and third-placed teams. This proposal will be submitted to the KHL Board of Directors for approval.

The Gagarin Cup playoffs were halted in the conference semifinals after Jokerit and Barys pulled out due to the coronavirus pandemic. Originally, the KHL was planning for a one-week break to come up with a new format for the four remaining teams. They later chose to end the season completely.

Im sure that the league has taken a fair and balanced decision in this difficult situation, said KHL president Alexei Morozov. This was the only choice that respects our sporting principles. For the first time in history, the KHL season had to be interrupted and ultimately curtailed. That was a tough, but essential decision, dictated by the need to protect the health of the nation.

MORE: Bill Peters signs two-year deal to coach KHLs Avtomobilist

Sean Leahy is a writer for Pro Hockey Talk on NBC Sports. Drop him a line at phtblog@nbcsports.com or follow him on Twitter @Sean_Leahy.

Brendan Leipsic of the Capitals has apologized for comments made on social media that were leaked online Wednesday. Panthers prospect Jack Rodewald was also in the Instagram group chat where remarks were made about the appearances of Meaghan Pearson, whose husband, Tanner, plays for the Canucks, Lauren Kyle, the girlfriend of Oilers forward Connor McDavid, and other women.

Yesterday my friends Instagram account was hacked and an individual circulated images that are representative of private conversations I was a part of, Leipsic wrote in an apology note posted on Twitter. I fully recognize how inappropriate and offensive these comments are and sincerely apologize to everyone for my actions. I am committed to learning from this and becoming a better person by taking time to determine how to move forward in an accountable, meaningful way. I am truly sorry.

The NHL released a statement of their own stating they will address this with the players involved.

The National Hockey League strongly condemns the misogynistic and reprehensible remarks made by players Brendan Leipsic and Jack Rodewald in a private group chat that has surfaced on social media. There is no place in our League for such statements, attitudes and behavior, no matter the forum. We will address this inexcusable conduct with the clubs and players involved.

Leipsic, who has played 61 games with the Capitals this season, is on his fifth team in five years since entering the NHL. His current team wrote in a statement,We are aware of the unacceptable and offensive comments made by Brendan Leipsic in a private conversation on social media. We will handle this matter internally.

Sean Leahy is a writer for Pro Hockey Talk on NBC Sports. Drop him a line at phtblog@nbcsports.com or follow him on Twitter @Sean_Leahy.

Read the original here:
Laila Anderson on Couch2Cure event, importance of Be the Match registry - NBCSports.com

Recommendation and review posted by Bethany Smith

British Columbia Premier John Horgan has offered the NHL a place to play if the league can find a way to resume the season.

Speaking at a COVID-19 media briefing Wednesday, Horgan said he has written a letter to both NHL Commissioner Gary Bettman and NHL Players Association head Donald Fehr to let them know B.C. is a place to potentially restart the NHL assuming the games would be played without audiences, but instead played for television.

The NHL suspended its season March 12 with 189 regular-season games left.

Dr. Bonnie Henry, British Columbias provincial health officer, was asked Monday about Vancouver hosting NHL games with no fans and said: These are the types of things that we need to think about.

Ontario Premier Doug Ford said Tuesday the Maple Leafs parent company, MLSE, has been in contact with the province about the possibility of Toronto serving as a hockey pod for teams as well. Alberta Premier Jason Kenney and Bettman spoke last month about Edmonton as another potential hub city.

Laila Anderson continues to make an impact in the lives of others one year after she became part of the Blues run to the 2019 Stanley Cup title.

On Tuesday, Anderson, who has battled HLH, a disease that causes the body to make too many immune cells, took part in an all-day livestream event called Couch2Cure to benefit Be the Match. It served as not only a fundraiser, but also a call for people to become donors for patients seeking blood stem cell matches. She was joined by FOX play-by-play man Joe Buck and Blues PA announcer Tom Calhoun.

The event was a success, raising$1.45 million and resulting in 36,000 registries to the Be the Match program.

Laila spoke with NBC Sports Kathryn Tappen on Wednesday to talk about the Couch2Cure event, the importance of the Be the Match registry, and how shes doing one year after the Blues triumph.

MORE LAILA ANDERSON: Laila introduces Blues All-Stars with gusto Blues superfan enjoying life one year after bone marrow transplant Laila meets bone marrow donor Laila gets moment with Stanley Cup

Sean Leahy is a writer for Pro Hockey Talk on NBC Sports. Drop him a line at phtblog@nbcsports.com or follow him on Twitter @Sean_Leahy.

Welcome to the PHT Morning Skate, a collection of links from around the hockey world. Have a link you want to submit? Email us atphtblog@nbcsports.com.

A really nice read about ex-Blackhawks president John McDonoughs friendship with 11-year-old Cammy Babiarz, who is unable to walk or talk because of Rett Syndrome a rare developmental disorder. [Midway Minute]

It didnt last very long, but at one point in time Michael Jordan was a minority owner of the Capitals. [ESPN]

Economies are beginning to open up again, so too are hockey rinks in the U.S. [The Hockey News]

Georges Laraque opens about his up and down relationship with his father. [Vice]

How the 2011-12 Kings became unlikely Stanley Cup champions. [The Score]

Comparing Brady Tkachuks early days in the NHL to that of Mark Stones. [Silver Seven Sens]

What if some of NHLs all-time best hadnt run into historic dynasties? [Sportsnet]

Looking ahead to whats expected to be an intriguing 2022 NHL draft class. [Stephen Ellis]

Finally, the Wild music video you were looking for:

Sean Leahy is a writer for Pro Hockey Talk on NBC Sports. Drop him a line at phtblog@nbcsports.com or follow him on Twitter @Sean_Leahy.

After pulling the plug on the 2019-20 season in March, the KHL has decided there will be no champion and the Gagarin Cup will not be awarded for the first time in league history.

Due to this decision, the league has equally ranked the eight teams that advanced to the second round of the playoffs:Ak Bars Kazan,Barys Nur-Sultan,CSKA Moscow,Dynamo Moscow,Jokerit Helsinki,Salavat Yulaev Ufa,Sibir Novosibirsk, and SKA St. Petersburg.

From the KHL:

With the season incomplete, there is no way that a Gagarin Cup winner and other prize winners can be fairly chosen based on the results of the regular season. To announce a champion based on the regular season and one round of the playoffs would violate the sporting integrity of the competition.

The Russian Hockey Federation has drawn up a separate procedure to determine the Russian Champion for the 2019-20 season, and to award silver and bronze medals to the second and third-placed teams. This proposal will be submitted to the KHL Board of Directors for approval.

The Gagarin Cup playoffs were halted in the conference semifinals after Jokerit and Barys pulled out due to the coronavirus pandemic. Originally, the KHL was planning for a one-week break to come up with a new format for the four remaining teams. They later chose to end the season completely.

Im sure that the league has taken a fair and balanced decision in this difficult situation, said KHL president Alexei Morozov. This was the only choice that respects our sporting principles. For the first time in history, the KHL season had to be interrupted and ultimately curtailed. That was a tough, but essential decision, dictated by the need to protect the health of the nation.

MORE: Bill Peters signs two-year deal to coach KHLs Avtomobilist

Sean Leahy is a writer for Pro Hockey Talk on NBC Sports. Drop him a line at phtblog@nbcsports.com or follow him on Twitter @Sean_Leahy.

Brendan Leipsic of the Capitals has apologized for comments made on social media that were leaked online Wednesday. Panthers prospect Jack Rodewald was also in the Instagram group chat where remarks were made about the appearances of Meaghan Pearson, whose husband, Tanner, plays for the Canucks, Lauren Kyle, the girlfriend of Oilers forward Connor McDavid, and other women.

Yesterday my friends Instagram account was hacked and an individual circulated images that are representative of private conversations I was a part of, Leipsic wrote in an apology note posted on Twitter. I fully recognize how inappropriate and offensive these comments are and sincerely apologize to everyone for my actions. I am committed to learning from this and becoming a better person by taking time to determine how to move forward in an accountable, meaningful way. I am truly sorry.

The NHL released a statement of their own stating they will address this with the players involved.

The National Hockey League strongly condemns the misogynistic and reprehensible remarks made by players Brendan Leipsic and Jack Rodewald in a private group chat that has surfaced on social media. There is no place in our League for such statements, attitudes and behavior, no matter the forum. We will address this inexcusable conduct with the clubs and players involved.

Leipsic, who has played 61 games with the Capitals this season, is on his fifth team in five years since entering the NHL. His current team wrote in a statement,We are aware of the unacceptable and offensive comments made by Brendan Leipsic in a private conversation on social media. We will handle this matter internally.

Sean Leahy is a writer for Pro Hockey Talk on NBC Sports. Drop him a line at phtblog@nbcsports.com or follow him on Twitter @Sean_Leahy.

Read the original post:
NHL offered place to play in British Columbia - NBCSports.com

Recommendation and review posted by Bethany Smith

Unlike Type 1 or Type 2 diabetes, Type 3 diabetes isnt an official clinical diagnosis. Its not an established medical

Unlike Type 1 or Type 2 diabetes, Type 3 diabetes isnt an official clinical diagnosis. Its not an established medical term at least not yet, points out Guojun Bu, chair of the department of neuroscience at Mayo Clinic in Jacksonville, Florida. But experts say the concept is still a useful one that speaks to the link between insulin resistance in the brain and dementia caused by the progressive brain disorder Alzheimers disease.

Insulin, a hormone produced by the pancreas, regulates glucose levels in the blood. With insulin resistance, the cells dont respond well to the hormone. That can lead to higher blood-sugar levels and the development of Type 2 diabetes (and before that, prediabetes, a precursor to the chronic condition). Research shows that, even short of a person developing diabetes, insulin resistance can impact the body and brain and lead to a range of health complications.

The concept of Type 3 diabetes comes from the idea that insulin resistance is linked, in many cases, to Alzheimers dementia, making it yet another form of diabetes. Of course, the term is also an oversimplification, says Dr. Gary Small, a professor of psychiatry at the UCLA Semel Institute and author of The Small Guide to Alzheimers Disease, since the association isnt completely understood.

Where it breaks down is that its not a 100% link not all patients who have Alzheimers disease have insulin resistance, and not all people who have insulin resistance have Alzheimers disease, Small explains. Now one could argue it could be a subtype of Alzheimers disease where theres that link.

[See: 9 Habits That May Reduce Your Risk for Developing Alzheimers.]

Insulin Resistance Isnt Limited to Diabetes

Today, more than 30 million people in the U.S. have diabetes, according to the Centers for Disease Control and Prevention. And many more people have insulin resistance which isnt routinely tested for.

Even though insulin resistance is associated with diabetes, its much more common than diabetes, says Suzanne Craft, a professor of gerontology and geriatric medicine and director of the Alzheimers Disease Research Center at the Wake Forest School of Medicine in Winston-Salem, North Carolina. It can lead to diabetes, but it can also cause a host of other complications Alzheimers disease being one of those. Those who have insulin resistance, particularly at mid-life, are at greater risk for developing Alzheimers disease, Craft says.

There is a lot of literature supporting the association between insulin resistance and various types of dementias that disproportionately affect older patients, particularly Alzheimers disease, echoes Dr. Samoon Ahmad, a professor of psychiatry at the NYU Grossman School of Medicine and founder of the Integrative Center for Wellness in New York City. Insulin resistance in Alzheimers is a growing area of focus. As noted in a 2018 review article in the Frontiers in Neuroscience, The epidemiological connection between diabetes, obesity, and dementia represents an important public health challenge but also an opportunity to further understand these conditions. The key intersection among the three diseases is insulin resistance.

The association also applies to conditions that are related to insulin resistance, including Type 2 diabetes and obesity, notes Christian Pike, a professor in the Leonard Davis School of Gerontology at the University of Southern California.

Researchers arent exactly sure why insulin resistance is associated with higher rates of Alzheimers disease and related forms of dementia. But theres no shortage of theories and possible mechanisms that have been suggested to explain the relationship. And, generally speaking, its well-known that insulin plays an important role in brain function.

Insulin basically transports glucose from the bloodstream into cells, Small says. So that makes sense if your insulin transport system getting those nutrients to brain cells is not functioning properly, that the brain is not being fed its main energy source as well.

Insulin has a number of important roles to play in healthy brain function, Craft notes. Accordingly, she says, there are several pathways through which insulin resistance could increase the risk for Alzheimers disease. For one thing the hormone helps brain cells form connections. It helps the brain repair itself from injury and generate new brain cells, Craft says. It plays a very important role in memory.

So dysfunction in regards to how insulin is used or isnt can have a meaningful impact on cognitive function. Insulin resistance, by definition, is the brain not responding normally to insulin, Craft explains. So by depriving the brain of all of these various functions of insulin, insulin resistance creates an environment in the brain that makes it vulnerable to developing the kind of injury thats associated with Alzheimers disease.

Given the important role of insulin, it could be used as a possible treatment for mild cognitive impairment and Alzheimers disease, as noted in a 2018 research review published in the Journal of Neurology. Insulin delivered through a nasal spray, for instance, has been shown to improve recall of story details or story recall in patients with Alzheimers or mild cognitive impairment.

Ultimately, insulin may be delivered as a means to improve or at least stabilize cognition in people with Alzheimer and other dementias. In limited studies, intranasal insulin delivery has been shown to lead to some cognitive benefits in dementia patients, Pike points out.

Theres evidence that the Alzheimers brain may be less sensitive to insulin, which is critical for memory formation and maintenance, Bu adds. But more research is needed to explore the possibilities for managing or treating Alzheimers with insulin.

In the meantime, whats already well established is that preventing insulin resistance can protect a persons overall health including brain health.

[See: 10 Myths About Diabetes.]

Preventing Insulin Resistance Through Lifestyle Changes

Factors out of ones control namely genetics, having a family history of insulin resistance or diabetes can predispose a person, or raise ones risk of developing insulin resistance. But lifestyle still plays an outsized role in preventing it.

Lifestyle changes are among the most effective ways of preventing or delaying Alzheimers disease, too. And they are recommendations weve all heard before, Craft says.

Those include:

Getting regular exercise.

Consuming a healthy, balanced diet.

Maintaining a healthy weight.

If a person did all of those things, the rate of insulin resistance would be dramatically reduced, Craft says.

What we dont understand is why some people have a greater tendency to develop insulin resistance than others, even when their diets and levels of exercise are more or less than the same, Ahmad says. Genetics is likely one answer, but there may be other factors we are not aware of, and these may complicate the association between Alzheimers risk and diet.

Even so, the role of lifestyle remains important. While some individuals are at a significantly higher risk of developing either diabetes or Alzheimers because of genetic factors, getting regular exercise and eating healthy will certainly lower ones risk of developing Type 2 diabetes and could lower ones risk of developing Alzheimers disease, Ahmad adds.

Federal physical activity guidelines suggest getting at least 150 minutes of moderate intensity exercise, like brisk walking, weekly. Shifting to a sustainable, well-rounded, balanced eating pattern rather than say an extreme diet is also encouraged.

While most people like to hear about fad diets that produce unrealistic or unsustainable results, the best way to plan ones meal is to avoid excessive amounts of alcohol and processed foods particularly those high in saturated fats and sugars and to try to eat foods that are as close to their whole or natural states as possible, Ahmad says. This means a diet that is rich in whole grains, lean proteins, and fruits and vegetables, particularly raw fruits and vegetables.

From improving heart health to brain health and staying disease-free in general for as long as possible data strongly suggests turning away from a traditional Western diet thats heavily processed and high in saturated fat and sugar. This type of eating pattern has been linked with a higher risk of Alzheimers disease.

[See: Best Foods for Brain Health.]

The kind of diet that protects the brain is generally a Mediterranean-style diet that includes fresh fruits and vegetables, legumes, healthy fats from omega-3s which are anti-inflammatory, Small says. You can get omega-3 fats from fish and nuts. He notes that the fruits and veggies provide antioxidants and may fight against wear and tear from oxidative stress that causes damage to neurons over the years. A diet that limits refined sugars and processed foods will lower risk for Type 2 diabetes as well as Alzheimers dementia.

More from U.S. News

Got Diabetes? 7 Ways to Improve Your Sex Life

Diabetes Exercise Tips to Stay Safe While Being Active

9 Strategies to Reduce Falls for People With Dementia

Type 3 Diabetes? The Link Between Insulin Resistance and Alzheimer?s originally appeared on usnews.com

Read the original here:
Type 3 Diabetes? The Link Between Insulin Resistance and Alzheimer's - WTOP

Recommendation and review posted by Bethany Smith

It is possible to feel good and be resilient in times of stress, including the stressful time of menopause transition. The body changes of menopause can be detrimental to individual women, her community and the workplace. With Mothers Day on May 10 and Womens Health Week from May 10-16, addressing the impact of menopause is good for all in West Michigan.

When a woman crosses into menopause, her health is essentially as good as it is going to get. Menopause symptoms which include hot flashes, low sec drive and mood changes affect the quality of life for 80% of women, according to a 2015 study.

Menopause body changes lead to a dramatic increase in risk for obesity, heart attack, diabetes and depression. Because of this, hot flashes can be used to signal it is time to assess risk factors and make decisions about a womans health goals, lifestyle choices and treatment options. For example, estrogen is safer than many people think. Estrogen use early in menopause can reduce the risk for cardiovascular disease without increasing risk for breast cancer and while improving quality of life or a plant-based diet could reduce risk of heart attack.

The symptoms of perimenopause and menopause also can impact the bottom line for businesses. Scientific review of insurance claim data shows women with untreated symptoms of menopause hot flashes, night sweats had 57% fewer days of productive work, were more likely to miss days at work and have more medical office and ER visits with increased medical costs of $1,346 per patient per year, according to a 2015 study. Health care visits for women with symptoms totaled more than $340 million in direct cost, and the total cost of lost work was $28 million.

Experts say these symptoms and the related health consequences lead women to be more likely to leave the workforce or have their careers affected just at the time of potential upswing or promotion. Companies would benefit from increased attention to the benefits of addressing employee health needs around the menopause transition.

Menopause also affects our community by its effect on a womans sense of self, her work life and her family life. It is time to expand the conversation and better care for our community. Menopause happens to all women, either naturally around age 52 or prematurely as a result of cancer treatment or removal of the ovaries due to surgery for cancer or benign conditions such as fibroids or endometriosis.

Women benefit when they are empowered with knowledge about symptoms and treatment options, including targeted lifestyle choices, hormone or other medication, or therapies such as acupuncture. Women whose symptoms are treated spend less time going to the doctor, more time engaged in activities and less prone to chronic illness. West Michigan-based True Womens Health, a midlife, menopause and sexual health wellness clinic, aims to equip women with the right tools and resources to support optimal health for each patient through the good and the bad times.

With Mothers Day and Womens Health Week in mind, it is crucial to continue healthy aging year-round. As a patient of mine who survived breast cancer and works as a supervisor on a factory floor said, The SEEDS (Seven Essential Elements of Daily Success) and medication you prescribed saved me. I am back and happy with my new normal.

She and others like her have proven to me that all women deserve choices on how to cope with their menopause journey, which is the ultimate goal for our True Womens Health patients. When this happens, the whole community will benefit.

Read more:
Continuing healthy aging through motherhood and beyond - grbj.com

Recommendation and review posted by Bethany Smith

As the rumblings of a pandemic began to be felt at the beginning of the year, scientists at Penn started work to develop a vaccine and assess possible treatments. But the scope of COVID-19 studies at the University goes much broader. Scientists whose typical work finds them investigating autoimmune disease, influenza, HIV/AIDS, Ebola, cancer, hemophilia, and more, are now applying their deep understanding of biology to confront a novel threat.

The more scientists and clinicians observe about the virus, the more avenues of investigation emerge, aiming to shed light on questions such as what happens once the virus enters the body, what treatments might be of benefit, and how society should take action to keep transmission low.

To dig into what scientists around campus are asking and learning, Penn Today spoke with several who have pivoted their research to focus on COVID-19. Their work, while in its early days, is in many cases already finding applications in the fight against this ferocious virus, and may well shape the next steps to defeat it.

Another respiratory infection, influenza, has been a focus of research led by Andrew Vaughan of the School of Veterinary Medicine. But Vaughan didnt hesitate to begin studies of the novel coronavirus once its eventual impact became apparent.

Its not a stretch for our lab, he says. All the projects in our lab focus on repair and regeneration of the lungs after injury. The majority of my studies are to some degree agnostic about what is causing the injury.

Earlier work by his group, for example, showed that a lung cell transplant could boost healing in mice affected by a severe bout with flu. Now, graduate students and research specialists in his labworking no more than two together at a time to maximize social distancingare conducting new experiments focused more specifically on the biology of SARS-CoV-2, alongside parallel efforts by Edward Morrissey from the Perelman School of Medicine (PSOM). Knowing that the Ace2 receptor on lung cells is the gateway for the virus into the human body, theyre genetically manipulating alveolar type-two lung cells, those that are particularly essential for continuing oxygen exchange deep in the lungs, to alter or block ACE2 gene expression to try to prevent viral entry.

These alveolar type-two cells seem to be particularly susceptible to injury in both influenza and perhaps even more so in COVID-19, says Vaughan. In a perfect world, you might be able to take these genetically edited type-two cells and use them as a cellular therapy. I dont know that this is going to happen in time to impact this pandemic, but even if the pathogen the next time around is slightly different, we may still be able to employ these types of regenerative responses to help the lung recover better from injury.

In a separate project, Vaughan is partnering with Penn Vets Montserrat Anguera to explore a curious feature of COVID-19 disease: the fact that more men than women become severely ill and die. A number of hypotheses have been put forward to explain the disparity, but the two labs are investigating one particular possibility.

Dr. Anguera had posted something on Twitter saying that the ACE2 gene happens to be on the X chromosome, meaning that women have two copies of it, says Vaughan. I immediately texted her and said, I think theres something to that.

Normally women inactivate one of their X chromosomes, but some genes can escape this inactivation. This means its possible women may have higher ACE2 expression than men. Somewhat counterintuitively, scientists have actually found that higher ACE2 levels actually reduce lung injury, even though ACE2 is also what the virus depends on to enter cells.

Hormone expression levels are, of course, another factor that may influence sex differences in disease. Together, Anguera and Vaughans groups are both studying ACE2 expression and exposing alveolar type-two cells to various hormones to see how expression of viral receptors, Ace2 and others, changes. Ultimately wed like to see if this changes susceptibility to infection, working with Susan Weiss and others, says Vaughan.

Individual differences in how people respond to infection may be influenced by their unique genomic sequences. Penn Integrates Knowledge Professor Sarah Tishkoff of PSOM and the School of Arts & Sciences, is probing the rich sources of genomic data her group already had in hand to look for patterns that could explain differences in disease susceptibility. As in Vaughan and Angueras work, ACE2 is a focus.

This gene is very important for general health, Tishkoff says. Women have two copies, men have one; it plays a role in regulating blood pressure; its in the kidneys; its in the gut. We want to understand the role that variation at this gene may play in risk for COVID-19, severity of disease in people with underlying health conditions, and differences in the prevalence of disease in men and women.

Using genomic data from 2,500 Africans collected for another project, Tishkoffs team is looking for patterns of genetic diversity. Early findings suggest that natural selection may have acted upon on version of the ACE2 gene, making it more common in some African populations with with high exposure to animal viruses.

Shes also collaborating with Anurag Vermaand Giorgio Sirugo of Penn Medicine to analyze genetic variation in samples from the Penn Medicine Biobank, looking in particular at people of African descent. Were seeing disturbing health disparities with COVID, with African Americans at higher risk for serious illness, says Tishkoff. This disparity mostlikelyhas to do with inequities in access to health care and socioeconomic factors, but were also looking to see if genomic variation may be playing a role.

Looking ahead, Tishkoff hopes to partner with Daniel Rader and others through the Center for Global Genomics and Health Equity to work with the West Philadelphia community. Wed like to do testing to understand the prevalence of infection and identify environmental and genetic risk factors for disease, she says.

The immune reaction to SARS-CoV-2 is a double-edged sword. The immune system is what eliminates the virus, says E. John Wherry of PSOM. The immune system is what we need to activate with a good vaccine. But also, especially in many respiratory infections, the immune system is what also causes damage. A healthy outcome means your immune system is striking a balance between killing off the virus and not doing so much damage that it kills you.

Wherry and PSOMs Michael Betts have embarked on a study to discern both the magnitude of patients immune responses as well as their flavor, that is, what components in the immune system are being activated by the coronavirus. Theyre doing so by working with clinicians at the Hospital of the University of Pennsylvania (HUP) and, soon, at Penn Presbyterian Medical Center, to collect blood samples from patients with severe and more mild infections, as well as patients who have recovered from illness, to profile their immune reactions.

Its one of the beautiful things about Penn. Everyone is working as a team, being selfless, being present, and bringing all their expertise to bear on this crisis. E. John Wherry, Perelman School of Medicine

We are observing a huge amount of heterogeneity across these patient samples, says Betts. But were also identifying some relatively unifying characteristics, indicating there are mechanisms that everyone uniformly uses to fight off this infection.

This variety across patients strongly suggests that the treatments that work for one patient may not for another, Wherry and Betts note. For that reason, they are speaking daily with their colleagues on the front lines of COVID-19 care, relaying what theyre finding out in the lab to adjust and personalize care in the clinic.

Its one of the beautiful things about Penn, says Wherry. Everyone is working as a team, being selfless, being present, and bringing all their expertise to bear on this crisis.

Plenty of recent scientific attention has been paid to the role of the gut microbiome in health. But the medical schools Ronald Collman and Frederic Bushman have been devoting attention to how the community of bacteria, viruses, fungi, and parasites that dwell in the respiratory tract affect health and disease risk. They are now addressing that question in the context of COVID-19.

There are two reasons were interested in studying this, Collman says. First is that the microbiome can help set the tone for the immune response to infections, influencing whether a patient ends up with mild or severe disease. And second, the microbiome is where infectious agents that can cause infection can arise from. So if a patient dies of an eventual pneumonia, the pathogen that caused that pneumonia may have been part of that individuals respiratory tract microbiome.

Working with nurses at HUP to collect samples, Collman and Bushman are analyzing the microbiome of both the upper (nose and throat) and lower (lung) portions of the respiratory tract of COVID-19 patients. These samples are being used by other groups, such as those developing diagnostic tests, while Collman and Bushmans labs work to identify the types and quantities of organisms that compose the microbiome to find patterns in how they correlate with disease.

Were hoping that if we can find that the response to the virus is different in people with different upper respiratory tract microbiomes, then we could manipulate the microbiome, using particular antibiotics, for example, to make it more likely that patients would have a mild form of the disease.

Absent a vaccine, researchers are looking to existing drugssome already approved by the U.S. Food and Drug Administration for other maladiesto help patients recover once infected. Throughout his career, Ronald Harty of Penn Vet has worked to develop antivirals for other infections, such as Ebola, Marburg, and Lassa Fever.

Our antivirals are sometime referred to as host-oriented inhibitors because theyre designed to target the interaction between host and viral proteins, says Harty. Though many of the biological details of how SARS-CoV-2 interacts with the human body are distinct from the other diseases Harty has studied, his group noticed a similarity: A sequence hes targeted in other virusesa motif called PPxYis also present in the spike protein of SARS-CoV-2, which the coronavirus uses to enter cells.

This caught our eye, says Harty, and piqued our interest in the very intriguing possibility that this PPxY motif could play a role in the severity of this particular virus.

Harty is testing antivirals he has helped identify that block the replication of Ebola, Marburg, and other viruses to see if they make a dent on the activity of SARS-CoV-2. Those experiments will be done in collaboration with colleagues whose labs can work in BSL-III or -IV laboratories, such as Penns Weiss.

Also of interest is the speculation that the coronavirus might disrupt cell-cell junctions in the human body, making them more permeable for virus spread. Hartys lab will be examining the potential interactions between the viral structural proteins and human proteins responsible for maintaining these cellular barriers.

Another faculty member is assessing whether a drug developed for a very different conditionin this case, pulmonary arterial hypertension (PAH)could serve coronavirus patients. Henry Daniell of the School of Dental Medicine recently shared news that a drug grown in a plant-based platform to boost levels of ACE2 and its protein product, angiotensin (1-7), was progressing to the clinic to treat PAH. Daniell is now working with Kenneth Margulies from Penn Medicine to explore whether this novel oral therapy can improve the clinical course of patients with symptomatic COVID-19 infection.

Reduced ACE2 expression has been linked to acute respiratory distress, severe lung injury, multi-organ failure and death, especially in older patients. The earlier preclinical studies in PAH animal models showed that orally delivered ACE2 made in plant cells accumulated ten times higher in the lungs than in the blood and safely treated PAH. Now, new clinical studies have been developed to explore whether oral supplementation of ACE2 and angiotensin-1-7 can help mitigate complications of COVID-19 disease. The fact that freeze-dried plant cells can be stored at room temperature for as long as a year and can be taken at home by COVID-19 patients make this novel approach an attractive potential option.

This trial has been given a high priority by the Penn Clinical Trial Working Group, says Daniell. Im pleased that this looks to be on the cusp of moving forward to help the growing number of COVID-19 patients.

As the coronavirus began to spread in the United States, biologist Joshua Plotkin of the School of Arts & Sciences began to raise alarms about Philadelphias St. Patricks Day parade, which had been scheduled to be held March 15, potentially drawing thousands to downtown streets. He had good reason to be concerned: His studies of the 1918 flu pandemic had explored disease incidence and spread, and it was hard to avoid noticing the role of the Liberty Loan parade down Broad Street in triggering a rampant spread of flu a century ago.

Now, with work conducted with two graduate students from Princeton University, Dylan Morris and Fernando Rossine, along with Princeton faculty member Simon Levin, Plotkin has mathematically sound advice for policymakers hoping to effectively stem the spread of a pandemic. In a preprint on arXiv.org, they share optimal, near-optimal, and robust strategies for how to time interventions such as social distancing.

This boils down to knowing what is the best way, of all the infinite possibilities, to intervene using public health measure, says Plotkin. Thats a problem we can solve with math, my colleagues Dylan and Fernando realized.

Their analysis makes the realistic assumption that policymakers can only enforce social distancing for a limited amount of time, and aims to minimize the peak incidence of disease. The optimal strategy, they found, is to start by introducing moderate social distancing measures to keep the incidence rate the same for a period of time. This would mean that every person with COVID-19 would infect one additional person. Then the intervention should switch over to a full suppressionthe strongest possible quarantinefor the rest of the period. At the end of that period, all restrictions would be lifted.

This works because you dont want to fully suppress disease spread right off the bat, says Plotkin, because then at the end, after you remove restrictions, there will be a second peak that is just as large as the first. By employing a moderate suppression at the beginning, youre building up a population of people who are going to recover and become immune, without letting the epidemic get out of control.

Unsurprisingly, timing is key. Attempting the optimal intervention would be disastrous, in practice, because of inevitable errors in timing. Intervening too early is pretty bad, because you get a bigger second peak, he says. But intervening too late is even worse. The key lesson is that a robust intervention is more important than an optimal one.

Plotkin and his colleagues are hoping to share the findings widely, including with local decision makers, to help them navigate a likely second wave of COVID-19.

Montserrat Anguera is an associate professor of biomedical sciences at the University of Pennsylvania School of Veterinary Medicine.

Michael Betts is a professor of microbiology at the University of Pennsylvania Perelman School of Medicine.

Frederic Bushman is the William Maul Measey Professor in Microbiology at the University of Pennsylvania Perelman School of Medicine.

Ronald Collman is a professor of Medicine at the University of Pennsylvania Perelman School of Medicine.

Henry Daniell is vice-chair and W.D. Miller Professor in the Department of Basic and Translational Sciences in the University of Pennsylvania School of Dental Medicine.

Ronald Harty is a professor of pathobiology and microbiology at the University of Pennsylvania School of Veterinary Medicine.

Kenneth Margulies is a professor of medicine and physiology and research and fellowship director of the Heart Failure and Transplant Program at the University of Pennsylvania Perelman School of Medicine.

Joshua Plotkin is the Walter H. and Leonore C. Annenberg Professor of the Natural Sciences in the Department of Biology at the University of Pennsylvania School of Arts & Sciences. He has secondary appointments in the Department of Mathematics and in the School of Engineering and Applied Sciences Department of Computer and Information Science.

Sarah Tishkoff is the David and Lyn Silfen University Professor with appointments in the Perelman School of Medicines Department of Genetics and the School of Arts and Sciences Department of Biology. A Penn Integrates Knowledge Professor, she is also director of the Penn Center for Global Genomics and Health Equity.

Andrew Vaughan is an assistant professor of biomedical sciences at the University of Pennsylvania School of Veterinary Medicine.

E. John Wherry is chair of the Department of Systems Pharmacology and Translational Therapeutics, director of the Institute for Immunology, and the Richard and Barbara Schiffrin Presidents Distinguished Professor at the University of Pennsylvania Perelman School of Medicine.

Homepage image: Researchers around the University are taking a variety of approaches to study the novel coronavirus (particles of which are shown in purple), informed by past expertise and newly formed collaborations. (Image: National Institutes of Health)

Continue reading here:
Coming together to solve the many scientific mysteries of COVID-19 - Penn: Office of University Communications

Recommendation and review posted by Bethany Smith

Release Date: May 5, 2020

BUFFALO, N.Y. Mary Wilson, wife of the late Buffalo Bills owner Ralph Wilson and a strong advocate of Western New York for the past 29 years, will be awarded the Chancellor Charles P. Norton Medal, UBs highest honor.

Jean Wactawski-Wende, SUNY Distinguished Professor in the Department of Epidemiology and Environmental Health and dean of the School of Public Health and Health Professions, and an internationally recognized researcher on womens health issues, will receive the UB Presidents Medal in recognition of extraordinary service to the university.

In addition, SUNY honorary doctorates are being presented to UB alumna Donnica L. Moore, president of the Sapphire Womens Health Group, and Richard A. Schatz, research director of cardiovascular interventions at the Scripps Heart, Lung and Vascular Center.

Wactawski-Wende will receive the Presidents Medal during the School of Public Health and Health Professions virtual commencement ceremony on May 16; the other award recipients will receive their honors at a later date.

Chancellor Charles P. Norton Medal

The Chancellor Charles P. Norton Medal is presented annually in public recognition of a person who has, in Nortons words, performed some great thing which is identified with Buffalo a great civic or political act, a great book, a great work of art, a great scientific achievement or any other thing which, in itself, is truly great and ennobling, and which dignifies the performer and Buffalo in the eyes of the world.

Announcing this years Norton Medal recipient, Jeremy M. Jacobs, chair of the UB Council, said that Mary Wilson a life trustee of the Ralph C. Wilson, Jr. Foundation richly deserves the honor for her longstanding commitment to the region.

This year, we were absolutely unanimous in our decision to honor Mary Wilson, he said. In her leadership of the Wilson Foundation, Mary is making an enduring and unprecedented impact on Buffalo and all of Western New York, which will be felt for many generations to come. Her dedication and work align perfectly with the spirit of the Norton Medal.

Wilson has been devoted to Western New York since she first arrived in the area for the Bills home opener in 1990.

She has spent many years developing her Western New York Girls in Sports program, which biannually brings more than 200 9- to 12-year-old girls together to take part in various sports taught by young athletes from local universities and sports clubs.

The program, now ensured to run in perpetuity, is organized by the United Way of Buffalo and Erie County through an endowment from the Ralph C. Wilson, Jr. Foundation.

She has also supported organizations benefiting communities in Buffalo, Erie County and Southeast Michigan, among them Hospice of Western New York, WNY Womens Foundation, Food Bank of Western New York, Albright-Knox Art Gallery, Girl Scouts of Western New York, the SPCA serving Erie County, the Buffalo Philharmonic Orchestra, the Alzheimers Association Greater Michigan Chapter, The Helm (formerly Services for Older Citizens), the Detroit Symphony Orchestra, the Detroit Historical Society and the Detroit Institute of Arts, to name a few.

UB Presidents Medal

The UB Presidents Medal, first presented in 1990, recognizes outstanding scholarly or artistic achievements, humanitarian acts, contributions of time or treasure, exemplary leadership or any other major contribution to the development of the University at Buffalo and the quality of life in the UB community.

President Satish K. Tripathi described recipient Jean Wactawski-Wende as a world-renowned epidemiologist who has brought great prominence to UB through her scholarly pursuits and academic excellence in the area of womens health.

A dedicated member of our university community for more than 30 years, Dr. Wactawski-Wende has made seminal contributions that have significantly impacted health care practice and disease prevention for women in the U.S. and around the world, he said.

Thanks to her tremendous leadership, she has further elevated the reputation of UB. Our university community, along with the many communities we serve, have been profoundly enriched by Dr. Wactawski-Wendes scholarship, teaching and service, and it is an honor to present the Presidents Medal to such a truly deserving recipient.

Of particular note is Wactawski-Wendes leadership role in the Womens Health Initiative (WHI), the largest longitudinal study of womens health in the United States. In 1993, she was part of the team that spearheaded UBs successful bid to become one of the federally funded studys 16 original vanguard clinical centers. Since the inception of the WHI, UB has received more than $30 million in funding from the National Institutes of Health to investigate health issues impacting postmenopausal women.

Among the WHIs major discoveries was the groundbreaking finding that intake of combined estrogen plus progestin was associated with an increased risk of heart disease, stroke and invasive breast cancer. That research, on which Wactawski-Wende served as a co-principal investigator, changed the use of hormone therapy in older women worldwide, potentially saving countless lives.

Through UBs current $6.2 million award extension of the WHI, she has overseen the continuation of research into many diseases associated with aging, such as cardiovascular disease, cancer, osteoporosis, stroke and dementia. She is also administering new studies that focus on frailty and predictors of healthy aging.

For those of us who know and have worked closely with Dr. Wactawski-Wende, we readily recognize the magnitude and excellence of her contributions to academic medicine, said Michael E. Cain, vice president for health sciences and dean of the Jacobs School of Medicine and Biomedical Sciences at UB.

She is an eminent and distinguished scholar and leader whose work, professional service, and stature in her discipline and research field are outstanding and continue to grow.

SUNY Honorary Doctorates

An internationally recognized womens health expert and advocate, Donnica L. Moore is president of Sapphire Womens Health Group, a multimedia firm that educates women about the benefits of a healthy lifestyle.

A pioneering physician, Moore utilizes public speaking and multiple media platforms including her own website and podcast to share impactful health information in laypersons terms.

She will receive a SUNY Honorary Doctorate in Science.

Dr. Moores significant accomplishments associated with women's health set an inspiring example for our university community and reflect the values of both UB and the SUNY system, Tripathi said.

Breaking barriers to educate women about an array of health-related topics, she has demonstrated a sustained and dedicated commitment to the well-being of women around the globe. One of UBs most distinguished alumni, Dr. Moore in utilizing accessible platforms to create broad access to sound, peer-reviewed medical information is enhancing lives in communities near and far.

Moore is a 1986 alumna of the Jacobs School of Medicine and Biomedical Sciences at UB, and underwent residency training in obstetrics and gynecology at Temple University, followed by a year of family medicine training at Memorial Hospital of Burlington, New Jersey.

She has appeared more than 800 times on such programs as The Oprah Winfrey Show, The Anderson Cooper Show and Good Morning America.

Richard A. Schatz is co-creator of the first coronary stent approved by the Food and Drug Administration for restenosis.

Known as the Palmaz-Schatz stent, this life-saving device has been used to treat coronary artery disease in nearly 100 million patients worldwide since its approval in 1994. It is considered one of the top 10 medical device patents of the past 50 years.

He will receive a SUNY Honorary Doctorate in Science.

Dr. Schatz is widely known as the father of modern interventional cardiology for good reason, Tripathi said. Every day, his groundbreaking work is realized in operating rooms across the country and beyond. The stent he co-created spurred a revolution in the treatment of coronary artery disease and, 30 years later, it has had an immeasurable impact on health care.

By contributing to society through his biomedical innovations and inventions, Dr. Schatz has improved the lives of tens of millions of people while embodying the ideals of our university community and our university system.

A New York native, Schatz is the research director of cardiovascular interventions at the Scripps Clinic and director of gene and stem cell therapy. He is an elected fellow of the American College of Cardiology. In 2019, he received the Fritz J. And Dolores H. Russ Prize, which recognizes biomedical engineering achievements that have significantly improved the human condition. He is also the recipient of the Barton Haynes Lifetime Scholar Award from Duke University Medical Center.

Schatz attended UB in the early 1970s before gaining early admission to Duke Medical School, then completed his cardiology training at Brooke Army Medical Center.

Throughout his career, he has maintained a strong affinity for UB, crediting the universitys faculty and curriculum for inspiring him to pursue a career in medicine.

Media Contact Information

See the original post here:
Mary Wilson to receive UB's Norton Medal - UB News Center

Recommendation and review posted by Bethany Smith

The latest lifestyle, fashion and travel trends

Missing your monthly facial?

Londons salons might be shut, but some of the citys savviest skin specialists have boxed up their bestselling treatments ready to pop in the post; allowing for a little me time before you FaceTime.

Mid-hibernation hydration

Contents of the Pfeffer Sal Essential Product Pack

The Pfeffer Sal clinic in Fitzrovia has earned its place in every London beauty editors little black book for its brand agnostic product recommendations and holistic-meets-high-tech approach. In order to keep their loyal clients GFH (glowing from home), the clinic has released six DIY facials, the best of which has to be the Essential product pack, based on the salons signature treatment. Included in the delivery are four full size products, among them an enzyme peel, a hydrating mask and Pfeffer Sals new own-brand Essential Serum a star blend containing four key actives that hydrate, stimulate collagen and elastin, and boost the skins regeneration. A virtual one-to-one with a therapist, normally 50, is also included, to ensure you peel and pamper like a pro.

Our top tip: Book the guided facial in the evening and leave the mask on to work its magic overnight

Pfeffer Sals Essential At-Home Product Pack, 250. Shop it here

The socially distanced detox

Antioxidant probiotic skin supplement from the Beauty Chef, included in the Skinwork Detox Facial in a Box

Thought this makeup-free WFH life was set to be a holiday for your skin but instead find yourself suffering with blackheads and breakouts? Youre not alone. The global pandemic-induced raising of stress levels increases production of the hormone cortisol, which in turn triggers overproduction of sebum. More sebum means more spots - but dont panic. LA import Skinwork, based in the Alex Eagle store in Soho, has a Detox Facial in a Box thats a one-way ticket to zit-free Zooming. Book a 30-minute skin coaching session with one of their team wholl take you through a thorough cleanse and detoxifying mask, finishing with a powerful vitamin C serum that treats pigmentation and brightens skin. Alongside the two full-size products the kit contains a headband, cleansing mitt and an antioxidant probiotic skin supplement from the Beauty Chef to get you glowing inside and out.

Skinwork Facial kits start at 100; The Detox Facial kit is priced at 165. Shop it here

The planet-loving pamper

Evolve Beauty's facial in a box

If you like your skincare vegan, organic, natural and cruelty-free, the Get Up And Glow Facial In A Box from British brand Evolve Beauty could be the one for you. The company makes all its products by hand and in small batches at its Hertfordshire wind-poweredecostudio, using the most effective natural superfoods. The box, made using recycled packaging, contains five travel size products: a Gentle Cleansing Melt, a Miracle Mask, a Hyaluronic Serum, Hyaluronic Eye Complex and a Daily Renew Facial Cream, alongside a towel headband and a step-by-step guide on how to apply your goodies. Best for normal to dry skin types, this is aDIYfacial both your skin and the planet will thank you for.

Evolve Beautys Get Up And Glow Facial In A Box, 50. Shop it here

How to do an at-home facial, according to a skincare pro

The post-lockdown reveal peel

Feel like youve aged a year in the last two months? Our current hermit-like existence offers the perfect opportunity to try a temporary redness-inducing chemical peel. Brilliant for brightening, peels also treat fine lines, wrinkles and hyperpigmentation while deeply hydrating and restoring the skins barrier. Facialist Kate Kerr, whos normally based out of the agua Spa at the Sea Containers Hotel, has an intensive Peel in a Box treatment on offer which uses high dose retinol to stimulate skin renewal and collagen production to even skin tone and smooth its texture. Not for the faint of heart, the three-day process forces the skin into an active peeling phase; best approached before a socially distanced weekend indoors. Given the intensity of the products, its suited to those already using a 0.5 per cent or 1.0 per cent retinol every night, and a preliminary telephone consultation with one of the Kate Kerr team is a must.

Kate Kerrs Home Peel Box costs 295 and contains enough for three courses of peel. Shop it here.

Read more from the original source:
Facials in a box: the step-by-step salon skincare you can order to your door - Evening Standard

Recommendation and review posted by Bethany Smith

Ajay Rampal, CEO, IFFCO Poultry Image Credit: Supplied

With a vision for excellence and quality, IFFCO established in 1975 is an international group based in the UAE, which manufactures and markets a well-integrated range of mass-market food products, related derivatives, intermediates, and services. With a portfolio of over 80 brands, IFFCO has firmly established itself as one of the main and most diversified groups in the Middle East.

IFFCO acquired Al Khazna Farm in April 2008, a farm where the best chicken breeds are selected, raised and fed on a 100 per cent vegetarian diet, with zero antibiotic residue and hormone-free production, ensuring the delivery of safe, nutritious, and high-quality fresh chicken.

Today, Al Khazna is one of the leading brands in the market under the fresh chicken category. Al Khazna prides itself in being a pioneer in processes and new product development.

Keeping consumer requirements in mind, Al Khazna offers whole chicken, portions and pre-cut parts to cater to every need.

While commenting on the current trends in the poultry industry, Ajay Rampal, CEO, IFFCO Poultry, says, With the current global situation, we see a change in the buying behaviour of consumers. A trend which is fast catching on is online shopping for groceries and fresh produce. Keeping this in view, we have tied up with a number of online operators, besides being present on retailers webstores.

The fresh and high-quality chicken products are also daily transported to various retail outlets, hotels, catering companies, government sectors and many more locations across the UAE in its temperature-monitored vehicles. Al Khazna is certified with HACCP, ISO22000-2018, FSSC 22000-2018, Halal and ESMA certificates.

At Al Khazna, we commit to deliver the highest quality meat from farm to fork on the same day to ensure that our consumers enjoy the exquisite taste with high nutritional value, explains Rampal.

In a unique initiative, Al Khazna has associated with Dubai Cares this Ramadan to support the cause of child education. We strongly believe that education is the basic right of every child, says Rampal, adding, With every kilo of Al Khazna product that a consumer buys, we contribute towards this cause. This platform not only gives us but also our consumers an opportunity to share and support this noble initiative.

Visit link:
IFFCO: Delivering the highest quality poultry for all your cooking needs - Gulf News

Recommendation and review posted by Bethany Smith

This comprehensive Artificial Intelligence in Life Extension Market research report includes a brief on these trends that can help the businesses operating in the industry to understand the market and strategize for their business expansion accordingly. The research report analyzes the market size, industry share, growth, key segments, CAGR and key drivers.

New vendors in the market are facing tough competition from established international vendors as they struggle with technological innovations, reliability and quality issues. The report will answer questions about the current market developments and the scope of competition, opportunity cost and more.

Market Summary:

The Artificial Intelligence in Life Extension market is a comprehensive report which offers a meticulous overview of the market share, size, trends, demand, product analysis, application analysis, regional outlook, competitive strategies, forecasts, and strategies impacting the Artificial Intelligence in Life Extension Industry. The report includes a detailed analysis of the market competitive landscape, with the help of detailed business profiles, SWOT analysis, project feasibility analysis, and several other details about the key companies operating in the market.

This report studies the Artificial Intelligence in Life Extension market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Artificial Intelligence in Life Extension market by product type and applications/end industries.

Company Coverage (Sales Revenue, Price, Gross Margin, Main Products, etc.):

Google,, Facebook, IBM, Intel, Microsoft, Gero, Deep Genomics, IBM Medical Sieve, Google DeepMind (DM) Health, Babylon Health (iOS, Android), Turbine.ai, and Insilico Medicine

The final report will add the analysis of the Impact of Covid-19 in this report Artificial Intelligence in Life Extension industry.

CLICK HERE TO REQUEST A SAMPLE COPY

Artificial Intelligence in Life Extension in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting. A Artificial Intelligence in Life Extension Market provides an extensive view of size; trends and shape have been developed in this report to identify factors that will exhibit a significant impact in boosting the sales of Artificial Intelligence in Life Extension Market in the near future

Scope and Segmentation of the Report

The segment analysis is one of the significant sections of this report. Our expert analyst has categorized the market into product type, application/end-user, and geography. All the segments are analyzed based on their market share, growth rate, and growth potential. In the geographical classification, the report highlights the regional markets having high growth potential. This thorough evaluation of the segments would help the players to focus on revenue-generating areas of the Vertical Farming market.

Regional Analysis

Our analysts are experts in covering all types of geographical markets from developing to mature ones. You can expect a comprehensive research analysis of key regional and country-level markets such as Europe, North America, South America, Asia-Pacific, and the Middle East & Africa. With accurate statistical patterns and regional classification, our domain experts provide you one of the most detailed and easily understandable regional analyses of the Artificial Intelligence in Life Extension market.

Competitive Landscape:

The research report also studied the key players operating in the Artificial Intelligence in Life Extension market. It has evaluated and explained the research & development stages of these companies, their financial performances, and their expansion plans for the coming years. Moreover, the research report also includes the list of planned initiatives that clearly explain the accomplishments of the companies in the recent past.

Research Methodology

The research methodology of the market is based on both primary as well as secondary research data sources. It compels different factors affecting the Artificial Intelligence in Life Extension industry such as historical data and market trends, different policies of the government, market environment, market risk factors, market restraints, technological advancements, forthcoming innovations, and obstacles in the industry.

Table Of Content

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 North America

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2026

14 Analysts Viewpoints/Conclusions

15 Appendix

Moreover, the research report assessed market key features, consisting of revenue, capacity utilization rate, price, gross, growth rate, consumption, production, export, supply, cost, market size & share, industry demand, export & import analysis, and CAGR.

Artificial Intelligence in Life Extension Market Key players influencing the market are profiled in the study along with their SWOT analysis and market strategies. The report also focuses on leading industry players with information such as company profiles, products and services offered financial information of last 3 years, key development in past five years.

CLICK HERE TO KNOW MORE

About Us:

Market research is the new buzzword in the market, which helps in understanding the market potential of any product in the market. Reports And Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world.

For more detailed information please contact us at:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

See the original post:
Artificial Intelligence in Life Extension Market Countries Analysis Report 2020 by Industry Size, Share, Growth Rate and Revenue - Latest Herald

Recommendation and review posted by Bethany Smith

New York, May 05, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Food Additives Market 2020-2024" - https://www.reportlinker.com/p03571280/?utm_source=GNW Our reports on food additives market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising demand for processed food, increasing complexities in the food supply chain and growing demand for home food preservation. In addition, rising demand for processed food is anticipated to boost the growth of the market as well. The food additives market analysis includes application segment, product segment, and geographic landscapes

The food additives market is segmented as below: By Application Bakery and confectionery Beverages Convenience food Snacks Others

By Product Flavors and enhancers Acidulants Colorants Sweeteners Others

By Geographic Landscapes North America APAC Europe South America MEA

This study identifies the increasing adoption of organic and natural ingredients as one of the prime reasons driving the food additives market growth during the next few years. Also, rising trend of non-GMO ingredients and shelf life extension of food products will lead to sizable demand in the market. The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our food additives market covers the following areas: Food additives market sizing Food additives market forecast Food additives market industry analysis"

Read the full report: https://www.reportlinker.com/p03571280/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more:
The Global Food Additives Market is expected to grow by $ 8.86 bn during 2020-2024 progressing at a CAGR of 4% during the forecast period -...

Recommendation and review posted by Bethany Smith

You have access to this full article to experience the outstanding content available to SPE members and JPT subscribers.

To ensure continued access to JPT's content, please Sign In, JOIN SPE, or Subscribe to JPT

This paper presents a fatigue-prediction methodology designed to extend the life of unbonded flexible risers and improve the accuracy of floating production, storage, and offloading (FPSO) vessel response analysis. The methodology combines measured-motion-response, maritime-environment, and process data to improve traditional time-domain dynamic analysis models, along with machine-learning (ML) techniques to develop a heading model for the FPSO.

Life extension of unbonded flexible risers is a challenge because of uncertainties associated with key parameters driving deterioration, such as how the riser was designed, manufactured, and installed and how it is operated. Fatigue service life is calculated during the design phase using models based on field-specific environmental data derived for the area and loads for the required design conditions per project specifications and international standards.

Using real measured data from the riser motions and from environmental sources can reduce uncertainties significantly, improving life-extension analysis for fatigue and other failure drivers. These data, when combined with high-end engineering assessments and considerations on data reliability, provide better insight and contribute to continued operations with acceptable risk for the risers.

The complete paper presents a methodology that uses measured environmental data and FPSO and riser response data in an ML environment to build more-realistic riser-response and fatigue-prediction models. A case example is presented for the risers suspended from the FPSO Fluminense producing from the Bijupir and Salema fields offshore Brazil. Because FPSO heading is important for vessel dynamics, especially roll, and the vessel dynamics are a key factor in the riser dynamics at this field, initial focus was on predicting vessel heading relative to swell. The heading model developed by ML showed good agreement and was used as a key tool in a traditional fatigue analysis. This analysis was based on historical sea states from the last 2 years. The results show that the fatigue analysis from the design phase is conservative and lifetime extension is achievable.

Because the fully instrumented measurement campaign ended after 4 months, the work focused on using all captured data to provide improved insight and develop both traditional simulation and ML models. For future fatigue predictions based on the developed fatigue counter, the objective is to maintain accuracy with less instrumentation.

In the present phase, FPSO and riser-response data from the 4-month campaign have been used to establish a correlation between riser behavior, environmental data, and FPSO heading and motion. Calibration of a traditional numerical model is performed using measurement data along with a direct waves-to-fatigue prediction based on modern ML techniques.

The ongoing work illustrates how real environmental data and response monitoring can reduce uncertainties and improve and extend flexible-riser life.

The improved armor-wire-fatigue methodology developed in this project uses accurate motion-response sensors directly installed on the riser and interfacing FPSO structures. The response data are combined with measured environmental data to build more-realistic fatigue models. The objective is to develop a model that represents the real-life responses of the FPSO in various swell- and wind-driven sea states, defining with high accuracy the long-term characteristics of the riser system.

Access to high-quality environmental data for tail-end production and life-extension projects of older assets may be a challenge. Efficient use of existing environmental data improves understanding of environmental loadings. Wind, wave, and surface-current data from different sources are assessed and verified for quality and potential weaknesses under varying conditions.

Actual operational data such as topside and subsea pressures and temperatures from the production information system are used instead of design limits to increase accuracy of fatigue development. Integrating the operators process-instrumentation network and riser-status databases enables use of actual exposure conditions. Measurement data, component data, and new insight from the improved analytical models are visualized by live contextualized dashboards that provide all stakeholders with the same easy-to-access, relevant, updated, and consistent information.

The complete paper discusses environmental data and motion monitoring. Because vessel roll is a key factor for the riser bending near the hang-off where the bend stiffener is located, models need a good representation of the wind, current, swell, and vessel heading to perform reliable fatigue analysis. When high-quality field measurement data are available at good resolution, better understanding of the dynamics and model improvement is achievable within a reasonable time. However, for periods without access to environmental and motion response data, good analytical models for both vessel response and for global and local riser analysis are necessary.

Swell is important for total wave conditions in Brazilian waters and is important for roll motion, especially for free-weathervaning FPSOs. In sea states dominated by swell, good insight in the heading of the FPSO relative to the incoming swell is important. During sea states with high wind, the FPSO will align with the wind direction and may expose the vessel to beam sea swell, possibly giving higher roll motions.

A key activity in this project was to develop a heading model for the FPSO, predicting the weathervaning response from input of wind, waves, and surface current. The authors preferred approach was to use field measurement data and ML. The more data are obtained, the more the model improves. Thus far, the model is trained on average from 3-hour sea states, so, for transient conditions, inaccuracies are inevitable. The model is trained as more field measurement data become available, and significant improvements are seen from the initial models to the current model. Several different ML approaches were tested to find the best possible approach for the data set of 4 months with 3-hour statistical data, giving approximately 600 samples after 3-hour periods with nearly no motions removed.

The ML processes used for developing the heading model were also used for the prediction of FPSO and riser-motion responses. The objective was to obtain a sufficiently accurate model enabling reliable prediction of dynamic responses in time periods where no response measurements are available.

The complete paper outlines the model-training process. The ML models proved to be on the same level or better than a time-simulation model in predicting motion responses when both models were fed with similar input from the environmental conditions.

As Fig. 1 illustrates, compared with the original design analysis, the accuracies of ML predictions based on real environmental data and models trained on measured field data enable a step toward reliable dynamics in flexible-riser fatigue.

Developing a reliable online fatigue counter for the flexible-riser armor wires began with validating the available environmental data for the FPSO site. A site with a comprehensive measurement program for waves, current, and wind with good time resolution would have been preferable. However, in this project, a robust and accurate alternative was found.

This approach will be relevant for the majority of brownfield assets. Newer installations in deeper waters likely will have more onsite measurements to support integrity-management analytics.

When combining quality weather data and observations; field measurements of FPSO, turret, and riser motion; and normalized fatigue/damage curves derived from validated models, the live fatigue counter can be established. The fatigue counter will account automatically for bore pressures different from planned operational pressure, as well as environmental conditions experienced in the field. Depending upon conservatism built into the design phase, possible life extension may be achieved and documented. By forecasting planned changes to operational conditions or possible changes in annulus environments, future scenarios may be exploited efficiently by assuming that wave, wind, and current in the coming years, on average, will be similar to those of recent years.

The complete paper includes a detailed discussion of the criteria and process used to develop the fatigue counter.

See original here:
Fatigue Prediction for Extended Riser Life and Improved Vessel-Response Analysis - Journal of Petroleum Technology

Recommendation and review posted by Bethany Smith

Across the globe there has been a notable uptick in consumer interest in the provenance and standards of food products, while a surge in demand for fresh produce and packaged goods means shelf life extension and stability are paramount concerns for food manufacturers.

Thats why we will be shining the spotlight on both issues in an exclusive webinar on May 12, where Dr Lan Ban, Research & Development Director at Kemin Food Technologies, will be presenting expert insights.

According to the company: Food safety is every brands number one priority while keeping product fresh for longer allows business to optimise its returns.

However, meeting consumers demands for safe and high-quality food requires extensive understanding of the chemical and biological pathways that affect products.

Thats why in this presentation, Kemin will assess how minor, yet hugely important, ingredients such as antimicrobials play a pivotal role in delaying microbial growth and preventing foodborne illness, while simultaneously ensuring brand longevity and loyalty.

Key takeaways will include an understanding of common food safety and shelf life challenges, and listeners will be equipped with toolkit for the best use of antimicrobials to solve them and boost business outcomes at the same time.

Register for the webinar here.

Read more:
Shelf-life and food safety: Hear exclusive expert insights on two of the biggest industry challenges right now - FoodNavigator-Asia.com

Recommendation and review posted by Bethany Smith

Share0

Understanding and optimizing how vapour permeability so dramatically effects the shelf-life of products in MAP packaging materials is hard. There are two approaches the head in the sand approach or practical testing. Versaperm has introduced a MAP testing service to measure the critical vapour permeability for packaging and materials based around its new high-speed testing equipment which can often turn around results within 24 hours, instead of the weeks taken by conventional testing techniques.

Vapour permeability testing has led to a four to eightfold shelf-life extension for food some products. Getting it wrong can actually reduce shelf life and quality.

Versaperm can test and measure vapour permeability not just for clients material samples but also for their packed products in their MAP packaging for virtually any type of package or configuration. Permeability can not only be measured not just for common water vapour problems but for oxygen, carbon dioxide, ethylene, and all other MAP gases.

It is important to have the ability to measure both material samples and finished products as manufacturing, sealing and packaging processes can substantially change a packages permeability.

Results are accurate in the parts per million or parts per billion ranges depending on the material and vapour. Where desired Versaperm can also control environmental conditions such as temperature and pressure, even across diurnal and seasonal cycles.

As well as its sample testing Versaperm develops and manufactures its own ranges of vapour testing equipment which are used by companies, universities, and national standards laboratories around the world.

View post:
The Head in the Sand Approach to MAP And a product's shelf life extension - International Supermarket News

Recommendation and review posted by Bethany Smith

As parties to merger or acquisition agreements carefully review their agreements to see what, if any, impacts the COVID-19 pandemic may have, the recent decision from the U.S. District Court for the Southern District of New York inNewmont Mining Corp. v. AngloGold Ashanti Ltd.[i]provides meaningful guidance for the interpretation of Material Adverse Effect (MAE) provisions in agreements governed by New York law. On March 18, 2020, inNewmont Mining, the Southern District of New York granted summary judgment for the seller, AngloGold Ashanti, Ltd. on the buyers, Newmont Mining Corporations, claims for damages arising from the alleged breach of an MAE provision. The decision inNewmont Mining, while decided under New York law, reinforces the established principle under Delaware law that buyers face an uphill battle when trying to establish an MAE.

An MAE provision in a merger or acquisition agreement typically includes three parts: 1) the definition of an MAE; 2) exclusion from that definition; and 3) exceptions to the exclusions. This article will discuss each part in turn, and discuss theNewmont Miningcourts reasoning for granting summary judgment to the seller relating to each part. Before diving into the details, however, it is worth keeping a few general principles about the interpretation of MAE provisions in mind.

GENERAL PRINCIPALS

When determining whether there is a breach of an MAE clause courts take a seller-friendly perspective that requires a buyer to make a strong showing to invoke its rights under MAE provisions.[ii] Thus, the Delaware Chancery Court has quipped, [a] contractual material adverse effect . . . is like a . . . tornadofrequently alleged but rarely shown to exist.[iii]

Courts consider the MAE provision as a backstop protecting the [buyer] from the occurrence of unknown events that substantially threaten the overall earnings potential of the target [company] in a durationally-significant manner.[iv] As a result, courts consider whether the alleged material adverse change was within the contemplation of the parties at the time they executed the agreement, whether it was within the control of the parties, and the magnitude of the impact on the relevant partys business.[v] MAE provisions are read in the larger context in which the parties were transacting.[vi] Thus, as theNewmont Miningcourt noted, a short-term hiccup in earnings should not suffice; rather the Material Adverse Effect should be material when viewed from the longer-term perspective of a reasonable acquiror.[vii]

Lastly, while the law in New York and Delaware regarding the interpretation of MAE provisions is largely consistent, the burden of proof required differs. Specifically, under Delaware law, a buyer must prove an MAE with clear and convincing evidence, whereas, in New York, the standard is a preponderance of the evidence.[viii]InNewmont Mining, this distinction, along with factual differences, led the court to distinguishAkorn, Inc. v. Fresenius Kabi AG[ix] the 2018 Delaware Chancery Court decision that made headlines because it found the existence of an MAE sufficient to terminate a merger agreement.[x]

THE DEFINITION OF AN MAE

Agreements typically define an MAE as any event, development or condition occurring that has had, or would be reasonably expected to have, a material adverse effect on the business, financial condition or results of operations of the company and its subsidiariestaken as a whole. For example, inNewmont Mining, where the buyer acquired a gold mine (the Mine) that contained a high grade mill (the Mill) that the seller was building as part of its Mine Life Extension project (MLE2), the MAE provision in the stock purchase agreement (SPA) defined a Company Material Adverse Effect, in relevant part, as any change, effect, event, occurrence, circumstance or state of facts that . . . (ii) is or would reasonably be expected to be materially adverse to the business, results of operations, condition (financial or otherwise) of . . .the Mine.[xi]

Importantly, the MAE provision referenced the Mine as a whole, not the Mill. This was of critical importance inNewmont Mining, where the only MAEs alleged by the buyer resulted from alleged problems with the Mill.[xii] As the court explained: the construction of the Mill was not the only component of the MLE2 project Moreover, Newmont bought the entire Mine, not just the one Mill, and was aware that the Mill was still being commissioned at the time the transaction closed.[xiii]Thus, the court reasoned:

If Newmont wanted the Company MAE definition to include materially adverse effects measured in terms of the Mill, it should have bargained for such a definition. Notwithstanding Newmonts assertion that the Mill was a hugely important piece of the [M]ine, and that it was the centerpiece and jewel of the transaction under the plain language of the SPA, Newmont must demonstrate that its Alleged MAEs had a materially adverse effect on the Mineas a whole.[xiv]

It thus concluded that Newmont had not established an MAE occurred because, [w]hile the percentage of gold expected to be recovered from Mill processing is not insignificant, and there may well be circumstances where an event involving the Mill does in fact constitute a materially adverse effect to the Mine as a whole, such circumstances are not present here.[xv]

Additionally, theNewmont Miningcourt highlighted that the buyers post-acquisition valuation of the Mine as a whole showed that no MAE had occurred. Specifically, the buyers post-acquisition valuation models showed that the Mine had increased in value after the transaction closed.[xvi] Thus, the court concluded that even if the Mill was underperforming, the buyers own analyses showed that the Mine as a whole did not suffer an MAE.[xvii]

EXCLUSIONS TO THE DEFINITION OF AN MAE

Second, MAE clauses usually exclude specified events, such as weather events, terrorism or military actions, general economic downturns, conditions existing generally within the companys industry, and other broad categories of market or credit conditions. InNewmont Mining,the SPA expressly listed certain exception to the definition of a Company MAE, including, among others, changes or circumstances relating to (a) the industries in which [the sellers] operate, (b) general economic effects or conditions affecting the Unites States or anywhere else in the world, (c) foreign exchange, equity or debt market conditions, (d) acts of God (including earthquakes, storms, fires, floods and natural catastrophes, and (e) the failure to meet any projections or forecasts (it being understood that that [sic] the facts or causes underlying or contributing to such failure may be considered in determining whether a Company Material Adverse Effect has occurred unless otherwise excluded pursuant to any of the other clauses of this definition).[xviii]

InNewmont Mining, the court found that the exclusions of projections and forecast was dispositive. The buyers alleged MAEs were tied to the Mills alleged inability to achieve two forecasted metrics, a design throughput of 250 short tons per hour, and a gold recovery rate of 76.5%. The court rejected the buyers argument that its alleged MAEs were premised on the underlying causes of the missed projections and not the projections themselves. The court so held because the buyers interpretation would transform an otherwise narrow carve-out into an exception that swallows the rule, as it would allow virtually any set of circumstances to constitute a Company MAE as long as it could identify a purported underlying cause for a failure to meet projections or forecasts.[xix] Thus, the court determined that the parties intent in including the parenthetical excepting underlying causes from the exclusion for projections was to clarify that, where an underlying cause or set of facts fits within the Company MAE definition but also results in a failure to meet a projection, that underlying cause or set of facts may still be asserted as a Company MAE even though it contributed to a missed projection.[xx] Thus, for example, if the Mill was destroyed, that event would not be excluded from the definition of an MAE simply because it also caused the Mill to not achieve certain projections.

EXCEPTIONS TO THE EXCLUSIONS

MAE provisions typically state that, with respect to some or all of the specified exclusions, they will not be excluded to the extent that they have disproportionately adversely affected the company and its subsidiaries (taken as a whole) as compared to others in the same industry. The exception to the specified exclusions was not an issue in theNewmont Miningdecision; however, such exceptions may become a focus of litigation in this post-COVID world. For example only, we expect that notwithstanding the severe economic impact that COVID-related disruptions have had on all businesses, buyers may attempt to find footing arguing that the impact on their recently-acquired or to-be acquired business was disproportionate or otherwise unique. The adjudication of such arguments will be fact intensive and require expert analysis.

CONCLUSION

COVID-19 will bring MAE provisions into the spotlight in M&A litigation as parties evaluate the impact to their soon-to-be or recently-acquired business. TheNewmont Miningdecision provides helpful guidance with respect to the requirement that alleged MAEs impact the acquisition target as a whole, and the interpretation of exclusions regarding the projections and forecasts that are typically included in MAE provisions.

[i]Newmont Mining Corp. v. AngloGold Ashanti Ltd., et al.,Opinion and Order, No. 1:17-cv-08065 (S.D.N.Y. Mar. 18, 2020), ECF No. 143 (Newmont Mining).

[ii]In re Ibp S'holders Litig. v. Tyson Foods, 789 A.2d 14, 144-45 (Del. Ch. 2001) (Tyson Foods).

[iii]Chyronhego Corp. v. Wight, No. 2017-0548-SG, 2018 Del. Ch. LEXIS 258, at *22 (Del. Ch. July 31, 2018)

[iv]Tyson Foods, 789 A.2d at 144.

[v]Newmont Miningat 34.

[vi]Tyson Foods, 789 A.2d at 141-42, 144.

[vii]Newmont Miningat 35 (quotingTyson Foods,789 A.2d at 68).

[viii]Tyson Foods, 789 A.2d at 94.

[ix]Akorn, Inc. v. Fresenius Kabi AG, et al.,Memorandum Opinion, No. 2018-0300-JTL (Del. Ch. Oct. 1, 2018) (Akorn).

[x]Newmont Miningat 46 n.30.

[xi]Id.at 2-3, 32-33 (emphasis added).

[xii]Id.at 39.

[xiii]Id.

[xiv]Id.at 39-40 (emphasis in original).

[xv]Id. at 40.

[xvi]Id.at 51-52.

[xvii]Id.

[xviii]Newmont Mining Corp. v. AngloGold Ashanti Ltd., et al.,The AGA Defendants Local Rule 56.1 Statement in Support of Their Motion for Summary Judgment at 242,supranote i,ECF No. 110.

[xix]Newmont Miningat 37.

[xx]Id.

1994-2020 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.

Read the original:
SDNY Ruling in Newmont Mining Lawsuit - The National Law Review

Recommendation and review posted by Bethany Smith

MIKE TYSON revealed how he has started training again having not thrown a punch for a staggering 15 years - and is being aided by stem-cell research therapy.

The Baddest Man on the Planet, who hung up his gloves in 2005 following defeat by Kevin McBride, wouldn't elaborate on why he was having the treatment but added that it was 'really wild what scientists can do'.

4

Tyson was having an Instagram chat with basketball legend Shaquille O'Neal when he revealed that he had been training for the previous three days after 15 years away - and his new health regime.

Iron Mike said: "You know what I had done? I had stem-cell research therapy.

"I feel like a different person but I can't comprehend why I feel this way. It's really wild what scientists can do."

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition that usually takes the form of a bone marrow transplantation.

He did not reveal what the exact condition was that was being treated.

Despite letting the gloves gather dust in the corner, it didn't take long for Iron Mike to show off that lethal punching power.

4

The 53-year-old delighted fans in lockdown by uploading a viral video of him laying into a punchbag with his trademark speed and power.

Tyson's weight ballooned after retiring following battles with drug addiction and depression.

But he has since partnered with a new trainer, MMA coach Rafael Cordeiro, to kick-start his training after sensationally revealing his 15-year break.

During their chat, basketball legend O'Neal revealed how he ached for three days after playing with his sons.

Tyson responded: "That's just because you haven't done it for a while.

WHAT IS STEM CELL TREATMENT USED FOR?

Stem cell transplants are carried out when bone marrow is damaged or isnt able to produce healthy blood cells.

It can also be used to replace damaged blood cells as the result of intensive cancer treatment.

Here are conditions that stem cell transplants can be used to treat:

"If you continue to do it consistently you'll be back to normal.

"It's just like me, I haven't boxed or hit the bag for 15 years - it has been three days so far and I feel incredible."

Tyson, who has a 50-6 record, is reportedly gearing up for a sensational return amid plans to compete in exhibition bouts for charity later this year.

He told rapper T.I. last month: "I've been hitting the mitts for the last week.

"That's been tough, my body is really jacked up and really sore from hitting the mitts.

MIKE DROPTyson shows off body transformation with 53-year-old preparing for boxing return

NO GLOVE LOSTJoshua tells Froch to 'shut up, blud' as war of words continues

HOLY MOLYHolyfield hints at comeback aged 57 after Tyson announces plans to return to ring

DO OR TYMike Tyson's trainer 'saw life flash before his eyes' in scary training clip

IT WILL ALL END IN PIERSPiers Morgan and Eddie Hearn in Twitter spat over coronavirus

HOME FIGHTERDubois enjoys lockdown sparring with siblings after buying family pad

SHOWDOWNHall vs Bjornsson: How giants compare as Beast threatens deadlift record holder

WHATSAPP-ENING?Joshua sent Froch four now-deleted messages after his P4P rant

SUMMER LOVIN'Boxing set for JULY return as chiefs outline safety plans for fan-free events

"I've been working out, I've been trying to get in the ring, I think I'm going to box some exhibitions and get in shape.

"I want to go to the gym and get in shape to be able to box three or four-round exhibitions for some charities and stuff.

"Some charity exhibitions, make some money, help some homeless and drug-affected motherf****er like me."

4

4

Go here to read the rest:
Mike Tyson, 53, reveals he had stem cell research therapy and hadnt hit bags for 15 YEARS before returning t - The Sun

Recommendation and review posted by Bethany Smith

A recent market study on the global Hematopoietic Stem Cell Transplantation (HSCT) market reveals that the global Hematopoietic Stem Cell Transplantation (HSCT) market is expected to reach a value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% during the forecast period (2019-2029). The impact of the COVID-19 pandemic on the global Hematopoietic Stem Cell Transplantation (HSCT) market is discussed in the presented study.

The Hematopoietic Stem Cell Transplantation (HSCT) market study encloses a thorough analysis of the overall competitive landscape and the company profiles of leading market players involved in the global Hematopoietic Stem Cell Transplantation (HSCT) market. Further, the presented study offers accurate insights pertaining to the different segments of the global Hematopoietic Stem Cell Transplantation (HSCT) market such as the market share, value, revenue, and more.

Request Sample Report @https://www.mrrse.com/sample/9594?source=atm

The following doubts are addressed in the market report:

Key Highlights of the Hematopoietic Stem Cell Transplantation (HSCT) Market Report

The presented report segregates the Hematopoietic Stem Cell Transplantation (HSCT) market into different segments to ensure the readers gain a complete understanding of the different aspects of the Hematopoietic Stem Cell Transplantation (HSCT) market.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/9594?source=atm

Segmentation of the Hematopoietic Stem Cell Transplantation (HSCT) market

Competitive Outlook

This section of the report throws light on the recent mergers, collaborations, partnerships, and research and development activities within the Hematopoietic Stem Cell Transplantation (HSCT) market on a global scale. Further, a detailed assessment of the pricing, marketing, and product development strategies adopted by leading market players is included in the Hematopoietic Stem Cell Transplantation (HSCT) market report.

Companies Mentioned in the Report

The report profiles key manufacturers in the hematopoietic stem cell transplantation (HSCT) Market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include Regen Biopharma, Inc., Escape Therapeutics, Inc., Lonza Group Ltd., and Pluristem Therapeutics Inc.

The global hematopoietic stem cell transplantation (HSCT) Market has been segmented as follows:

By Transplant Type

By Disease Indication

By Application

By Region

Buy This Report @ https://www.mrrse.com/checkout/9594?source=atm

Continue reading here:
Global trade impact of the Coronavirus Hematopoietic Stem Cell Transplantation (HSCT) Market Shares, Strategies and Forecast Worldwide, 2019-2027 -...

Recommendation and review posted by Bethany Smith

SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- BioCardia, Inc.[Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced data from a recent animal study performed by the Company that demonstrate meaningful improvements in heart function for subjects treated with its allogenic (from another donor, or off the shelf) neurokinin 1 receptor positive mesenchymal stem cell (NK1R+ MSC) program for heart failure, known as CardiALLO. In addition, the Company is planning further exploration and discussion with the U.S. Food and Drug Administration (FDA) on the use of its allogenic cells for COVID-19 related Acute Respiratory Distress Syndrome (ARDS).

In the 26 animals treated with both low dose and high dose NK1R+ MSC, echocardiographic measures of cardiac ejection fraction, fractional shortening and cardiac outflow were meaningfully improved, with all three measures being statistically significant for both dosage levels over control animals.

The CardiALLO cell therapy is being developed initially to treat heart failure patients whose cells do not qualify for its lead autologous cell therapy, CardiAMP (BCDA-01).

BioCardia Chief Scientific Officer Ian McNiece, PhD, said, In light of these positive data on our allogenic NK1R+ MSC therapy, we expect to meet our internal timeline to complete our submission to the FDA for our first indication for CardiALLO, and potentially receive IND acceptance by the end of the second quarter. The MSCs that were studied are subtypes of MSC that we have delivered previously in our co-sponsored trials, which we believe have enhanced potency over MSC generated from unselected bone marrow cells. We look forward to seeing additional data from this animal study that are currently being analyzed, including histology and pathology of the heart and lungs.

COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) Exploration

The Company also intends to submit an IND for the use of its NK1R+ MSC delivered via intravenous (IV) infusion for Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19.

Based on preliminary clinical reports on COVID-19, respiratory failure complicated by ARDs is the leading cause of death for COVID-19 patients.1 ARDS is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs.

The anti-inflammatory effects of MSC have been well-documented and MSC have been shown to reduce inflammation and injury in models of lung disease.2 The specific MSCs used in BioCardias allogenic cell therapy are expanded from cells selected for the presence of the NK1 receptor, which is known to bind to substance P, an important neuropeptide associated with inflammation throughout the body and a primary mediator of inflammation in the airways.3,4

Our NK1R+ allogenic MSC may have more potential than other MSC approaches being advanced today due to their interaction with Substance P, said BioCardia CEO Peter Altman, PhD. This COVID-19 related work will be the Companys first clinical investigation outside of the cardiac space and our first exploring therapy for the lung. A recent patent publication (US 2020/0101113 A1) shows that BioCardia has long intended for these remarkable reparative cells to be targeted for respiratory disorders, in addition to cardiovascular disease. Addressing inflammation in the lungs is an important contribution we may be able to make using our NK1R+ allogenic MSC therapy.

The Companys allogenic cells are expected to be manufactured at BioCardias clinical stage cell manufacturing facility in San Carlos, California.

About BioCardiaBioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP and CardiALLO cell therapies are the Companys biotherapeutic product candidates in clinical development. The Company's approved products include the Helix transendocardial delivery system and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix System and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.

Forward Looking Statements This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the development of NK1R+ cells for the treatment of heart failure and ARDS secondary to COVID-19, potential FDA IND acceptances, and potential FDA filings, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardias Form 10-K filed with the Securities and Exchange Commission on April 9, 2020, under the caption titled Risk Factors. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact: Michelle McAdam, Chronic Communications, Inc.michelle@chronic-comm.com(310) 902-1274

Investor Contact: David McClung, Chief Financial Officerinvestors@BioCardia.com(650) 226-0120

Go here to read the rest:
BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure -...

Recommendation and review posted by Bethany Smith

People with cancer who contract the new coronavirus appear to have a greater risk for severe COVID-19 illness and death, but this may depend on their cancer stage and the type of treatment they are receiving, according to recent research. In fact, those with early-stage cancer may fare as well as people who have not had cancer.

Researchers from some of the earliest and hardest hit epicenters of the COVID-19 pandemic described outcomes among cancer patients with the coronavirus (officially known as SARS-CoV-2) during a special session the American Association for Cancer Research (AACR) virtual annual meeting last week. Soon after the conference, another group of researchers published an analysis of mortality among cancer patients in New York City.

Early reports from China, where the pandemic originated in late December, showed that older people, those with compromised immune systems and those with underlying health conditions are more susceptible to severe COVID-19. One study saw a death rate of 6% for people with cancermore than twice as high as the overall estimated COVID-19 mortality rate in China, but lower than the rates seen in people with diabetes (7%) or cardiovascular disease (11%).

Chemotherapy medications and some targeted therapies for cancer can cause neutropenia, a temporary depletion of immune system white blood cells that fight infection. People who receive bone marrow stem cell transplants or CAR-T therapy or for blood cancers typically receive strong chemotherapy to kill off existing blood cells and make room for the new ones. Conversely, immunotherapies such as checkpoint inhibitors and CAR-T therapy unleash natural or engineered T cells to fight cancer, which in some cases can trigger an excessive immune response that leads to harmful inflammation.

Two reports at the AACR meeting provided updates from China. Li Zhang, MD, PhD, of Tongji Medical College described outcomes among 28 cancer patients with COVID-19 in Wuhan, the initial epicenter of the pandemic.

Seven had lung cancer and the remainder had 13 other cancer types. Just over a third had Stage IV, or metastatic, cancer. Nearly 30% acquired the coronavirus at medical facilities. About half had severe disease, 10 patients required mechanical ventilators and eight diedmostly from acute respiratory distress syndromegiving a mortality rate of 29%.

Although three quarters had ever undergone surgery, radiation or chemotherapy, a majority had not received treatment recently. Only one person received radiation, three received chemotherapy, two received targeted therapy and one received immunotherapy within two weeks prior to their COVID-19 diagnosis. Recent cancer treatment was associated with a fourfold increased risk of severe outcomes. However, the single patient treated with a checkpoint inhibitor (for liver cancer) had mild COVID-19 and a short hospital stay.

Similarly, as part of his discussion of immunotherapy for cancer in the COVID-19 era, Paolo Ascierto, MD, of the National Tumor Institute in Naples, noted that just two out of 400 patients on immunotherapy at his institute tested positive for the coronavirus, they were asymptomatic and they recovered quickly, leading him to speculate that immunotherapy might somehow be protective against COVID-19.

Hongbing Cai, MD, of Zhongnan Hospital of Wuhan University, presented data on 105 cancer patients and 536 age-matched people without cancer at 14 hospitals in Hubei province who developed COVID-19. Results were also published in Cancer Discovery. Twenty-two had lung cancer, 13 had gastrointestinal cancers, 11 each had breast cancer and thyroid cancer, nine had blood cancers such as leukemia or lymphomawhich affect white blood cells that carry out immune responsesand six each had cervical and esophageal cancer.

In general, patients with cancer deteriorated more rapidly than those without cancer, Cais team reported. Cancer patients with COVID-19 were nearly three times more likely to have severe or critical illness (34%), be admitted to an intensive care unit ICU (19%) or be put on a ventilator (10%). Whats more, people with cancer were about twice as likely to die as COVID-19 patients without cancer (11% versus 5%, respectively).

People with blood cancers or lung cancer, as well as those with metastatic cancer, had a higher risk of severe events. Two thirds of the blood cancer patients and half of the lung cancer patients had such events. Among the lung cancer patients, 18% were put on ventilators and 18% died. In contrast, no one with breast, thyroid or cervical cancer required ventilators or died.

In particular, those with blood cancersmore than half of whom had severe immune suppressionhad about a 10-fold higher risk of severe events or death. Two thirds had severe symptoms, 22% were put on ventilators and 33% died. These patients all had a rapidly deteriorated clinical course once infected with COVID-19, the researchers wrote.

People with metastatic cancer had about a six-fold higher risk of severe events or death. But people whose cancer had not yet spread were not significantly more likely to have severe events or die than COVID-19 patients without cancer. People currently on cancer treatment and those with a history of cancer who had completed treatment were both at higher risk.

People who underwent surgery within the previous 40 days had higher rates of severe events, ICU admission, ventilator use and death, but this was not the case for those who received only radiation. In this study, unlike Zhangs and Asciertos, people treated with immunotherapy did not fare so well. Four of the six patients who recently received checkpoint inhibitors had critical symptoms and two died.

Based on our analysis, COVID-19 patients with cancer tend to have more severe outcomes when compared to the non-cancer population, the researchers wrote. Although COVID-19 is reported to have a relatively low death rate of 2% to 3% in the general population, patients with cancer and COVID-19 not only have a nearly three-fold increase in the death rate than that of COVID-19 patients without cancer, but also tend to have much higher severity of their illness.

In a related study, Marina Chiara Garassino, MD, of Fondazione IRCCS National Tumor Institute in Milan, presented the first data from the international TERAVOLT registry, which is collecting data about COVID-19 among people with lung cancer and other thoracic malignancies. She noted that TERAVOLT was registering around 70 new cases per week from around the world per week.

This population may be especially vulnerable to COVID-19 due to older age, lung damage, smoking and underlying health conditions, Garassino said. Whats more, the symptoms of COVID-19 overlap with lung cancer, making diagnosis very challenging.

Garassino described results from the first 200 cancer patients with COVID-19 in more than 20 countries. Non-small-cell lung cancer was the most common type, and nearly three quarters had metastatic disease. About 20% received only targeted therapy, 33% received chemotherapy alone and 23% received immunotherapy alone.

A majority (76%) were hospitalized, but most were not offered intensive care for COVID-19; just 9% were admitted to an ICU and 3% were put on ventilators. More than a third (35%) died, mostly due to COVID-19 rather than cancer. Specific types of cancer treatment were not significantly associated with an increased risk of death.

But not all studies have seen worse COVID-19 outcomes among people with cancer. Fabrice Barlesi, MD, PhD, and colleagues looked at 137 COVID-19 patients with cancer at Gustave Roussy, a cancer center near Paris. They had a variety of cancer types, with blood cancers and breast cancer being most common. Nearly 60% had active advanced disease while 40% were in remission or being treated with potentially curative therapy.

Within this group, 25% had worsening COVID-19 after admission, 11% were admitted to the intensive care unit (ICU) and 15% died. Again, people with blood cancers were more likely to have worse outcomes. Treatment with chemotherapy within the past three monthsbut not targeted therapy or immunotherapydoubled the likelihood of worsening disease. But this only applied to people with active or metastatic cancer, not those who had localized disease or were in remission.

The 15% death rate among people with cancer at Gustave Roussy was lower than the 18% rate for all COVID-19 patients in Paris and in France, Barlesi said. His team concluded that both incidence and outcomes of COVID-19 among cancer patients seem to be comparable to the population as a whole. However, people with blood cancers, those treated with chemotherapy and frail patients are at greater risk.

Discussing how to manage cancer patients during the COVID-19 pandemic, Cai recommended self-protective isolation, strict infection control in hospitals and shifting some medical services online.

With regard to cancer treatment, she said, clinicians need to develop individualized plans based on a patients tumor type and stage of disease. She added that postponing surgery, if appropriate, should be considered in areas with current outbreaks. Radiation therapy, she said, could go ahead according to existing treatment plans with intensive protection and surveillance. Whether people with early-stage cancer need to postpone their treatment remains an unanswered question, she said.

Click hereto read the abstracts from the AACR COVID-19 and cancer session.Learn about What People With Cancer Need to Know About the New Coronavirus.

View post:
Cancer Patients With COVID-19 May Have Higher Risk of Severe Illness and Death - Cancer Health Treatment News

Recommendation and review posted by Bethany Smith

The first-in-human, universal chimeric receptor antigen (CAR) T-cell (CAR-T) therapy GC027 was tolerable and resulted in antileukemic responses among patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL), according to results from a phase 1 trial presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I 2020.1

Theuniversal CAR T cells target CD7, which, according to Xinxin Wang, PhD, ofGracell Biotechnologies Co, Ltd, in China, and lead author and presenter of thestudy, is a good target for T-ALL because it is expressed by more than 95% ofT-ALL patients.

GC027 isallogeneic, which may prevent the development of graft-versus-host disease. Theproduct is introduced using lentivirus for rapid elimination of T-ALL cells. Preclinicalstudies showed efficacy in a T-ALL xenograft model, and this prospective studyevaluated the safety and efficacy in humans.

Thesingle-arm, open-label study treated 5 adult patients with relapsed/refractoryCD7-positive T-ALL with a single infusion of 1 of 3 different dose levels ofG027: 0.6 x 107/kg, 3 x 107/kg, and 1.5 x 107/kg.Lymphodepletion therapy was administered prior to the G027 infusion. Theprimary endpoint was safety and the secondary endpoints included objectiveresponse rate (ORR) within 3 months after G027 infusion.

Patientswith extramedullary or central nervous system disease were excluded. Atbaseline, the median age was 24 (range, 19-38). Patients were heavilypretreated, with 5 median number of prior therapies (range, 1-9). Two patientshad high-risk disease and the median bone marrow tumor burden was a median of38.2% of blasts. None of the patients had undergone a prior allogeneic hematopoieticstem cell transplant.

Allpatients developed cytokine release syndrome (CRS), 4 of which were grade 3 and1 was grade 4. All cases were manageable and resolved with treatment andsupportive care. None of the patients developed neurotoxicity.

The completeremission (CR)/CR with incomplete hematologic recovery was 100%. By day 28, 4patients achieved a CR with negative for minimal residual disease (MRD) and 3of these patients remained MRD negative up to day 161. One patient achieved CRbut was MRD positive, and relapsed by day 29.

Peak CART-cell expansion in peripheral blood occurred between week 1 and 2.

As the first-in-human, universal CAR T-cell therapy for adult relapsed/refractory T-ALL, Dr Wang said, GC027 has demonstrated superior clinical efficacy and induced deep response in patients with acceptable safety profile. She added that trial enrollment is ongoing.

Reference

Wang X, Li S, Gao L, et al. Clinical safety and efficacy study of TruUCAR GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). Presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting I; April 27-28, 2020. Abstract CT052.

This article originally appeared on Cancer Therapy Advisor

Go here to see the original:
First-in-Human Universal CAR-T Therapy Found Active in Relapsed/Refractory T-ALL - Oncology Nurse Advisor

Recommendation and review posted by Bethany Smith

A novel,bispecific CD19/CD22 chimeric antigen receptor T-cell (CAR-T) therapy wastolerable and resulted in responses among patients with acute lymphoblasticleukemia (ALL), according to results from a phase 1 trial presented at the AmericanAssociation for Cancer Research (AACR) Virtual Annual Meeting I 2020.

Thenovel CAR-T therapy was developed with the hypothesis that dual antigen-targetingstrategies may prevent antigen negative escape, Haneen Shalabi, DO, of theNational Cancer Institute and lead author and presenter of the study, said.

Thephase 1, dose-escalation study treated 13 young patients with ALL with theCD19/CD22 CAR-T therapy at 3 different dose levels, including 3 x 105,1 x 106, and 3 x 106. The bispecific construct containedFMC63 (CD19 scFv) linked with m971 (CD22 scFv) and a 4-1 BB costimulatorydomain.

Patientsunderwent lymphodepletion with fludarabine plus cyclophosphamide prior to theirCAR-T infusion. The primary endpoints were safety and toxicity, and thesecondary endpoints were efficacy, chimeric antigen receptor (CAR) expansion,and CAR persistence.

Atbaseline, the median age was 19.6 (range, 5.4-28.5). Patients had receivedprevious treatments, including hematopoietic stem cell transplant (54%),CD19-targeted therapy (69%), prior CD19 CAR T cell therapy (38.4%),blinatumomab (61.5%), CD22-targeted therapy (38.4%), inotuzumab (30.7%), andCD22 CAR-T therapy (15.4%). Extramedullary disease was present in 46.2% ofpatients.

CAR Tcells were well tolerated and toxicities were reversible in all patients, DrShalabi said.

Cytokinerelease syndrome (CRS) developed in 46% of patients, 15.4% of which was grade 3or higher. Both patients who developed grade 3 or higher CRS had received the 1x 106 dose level of the CD19/CD22 CAR-T product and both requiredtreatment with tocilizumab. One patient developed neurotoxicity, and hadreceived the 3 x 106 dose level.

Of the12 patients evaluable for efficacy, a complete response (CR) was achieved by42% (5) of patients, including all patients who received the 1 x 106 or 3 x 106 dose levelsof the CD19/CD22 CAR-T therapy. There were 2 nonresponders.

Two patientswho received 1 x 106 CAR-T and all patients who received the 3 x 106dose level were negative for minimal residual disease (MRD), with the remainingCRs demonstrating bone marrow clearance. Four of the 5 patients who were MRDnegative were also naive to CAR-T therapy.

Of the 5patients who achieved a CR, 2 relapsed with CD19-positive/CD22-positive diseaseand 3 remained in remission at a median 7 months after CAR T cell infusion.

Severalpatients, however, who were MRD negative in the bone marrow did not achieve CRin their extramedullary disease. Dr Shalabi said that these discrepant resultsbetween marrow and extramedullary disease suggests potentially limited CAR-Ttrafficking to sites of extramedullary disease. She suggested that treatmentat higher dose levels may be needed to overcome this limitation.

CAR T-cellexpansion occurred in all patents who responded, with a median peak inperipheral blood of 7%. At day 28, there were 1.3% CAR T cells in the bonemarrow. The persistence of the CAR T cells in peripheral blood was a median of45.6 days, as measured by flow cytometry.

Dr Shalabi concluded that this early experience with bispecific CD19/CD22 CAR T cells demonstrates clinical activity with reversible CRS and limited neurotoxicity. She noted that future studies will explore a 1 x 107 dose level, intensification of lymphodepletion prior to CAR-T infusion, and consideration of the potential role of immune checkpoint inhibitors to augment CAR-T in extramedullary disease.

Read more of Cancer Therapy Advisors coverage of AACR 2020 meeting by visiting the conference page.

References

Shalabi H, Yates B, Shahani S, et al. Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL. Presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting I 2020; April 27-28, 2020. Abstract CT051.

Read the rest here:
Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL - Cancer Therapy Advisor

Recommendation and review posted by Bethany Smith

As the world continues to battle the coronavirus pandemic, scientists are looking towards gene therapy to find ways to develop vaccines for the Covid-19 virus. Gene therapy itself was developed based on how viruses work.

When a virus attacks a host, it introduces its genetic material into the host cell as part of its replication cycle. The genetic material serves as an instruction manual on how to produce more copies of the virus, hijacking the host body's normal production machinery to serve the needs of the virus. The host cells then produce additional copies of the virus, leading to more host cells being infected.

Like animals, humans have found a way to domesticate viruses as well, i.e., direct the virus's function to achieve favorable results, which is prominent in gene therapy. Such viruses which physically insert their genes into the host's genome could instead be used to carry "good" genes into a human cell. Scientists would first remove the genes in the virus that cause diseases, and replace those genes with genes encoding the desired effect.

All of this sounds quite sci-fi but it has been done numerous times in the past. Peter Kolchinsky, a virologist and a biotechnology investor, compiled how different viruses have been used for gene therapy in the past.

Kolchinsky tweeted, "SARS2 is a scary menace, but did you know that we've domesticated viruses? Like wolves vs dogs, we've tamed them, including some deadly ones, to perform many useful functions (and may help us stop SARS2)."

The human immunodeficiency virus (HIV) has killed millions of people. It works by disabling the host body's immune system until it can't defend the person against common, normally mild pathogens. Kolchinsky explained that HIV's special trick is to integrate its genome into that of the host body's cells.

This feature of HIV is used for gene therapy, as explained before, by replacing a chunk of the virus's genome with the hemoglobin gene to insert it into bone marrow stem cells of patients with sickle cell anemia, whose hemoglobin genes are malfunctioning.

Kolchinsky also tweeted, "Adenoviruses typically cause mild infections, including common colds. These, too, we are trying to use for gene therapies, particularly when we just want to temporarily make a protein in cells. One company is developing such an adenovirus gene therapy for heart disease to induce growth of new blood vessels when old ones are clogged. Another is using this virus to make oral vaccines that would otherwise require injection (eg flu vaccine pill). When we use a virus to deliver code for making something in cells, we call that a virus vector."

There is now a wealth of clinical experience with numerous vector types that include primarily vaccinia, measles, vesicular stomatitis virus (VSV), polio, reovirus, adenovirus, lentivirus, -retrovirus, adeno-associated virus (AAV) and herpes simplex virus (HSV).

However, as with all other procedures, viral vector-gene therapy has associated risks. Viruses can usually infect more than one type of cell, so, when viralvectorsare used to carrygenesinto the body, they might infect healthy cells as well as cancer cells.

Another danger is that the new gene might be inserted in the wrong location in the DNA, possibly causing harmful mutations to the DNA or even cancer. Moreover, when viruses are used to deliver DNA to cells inside the patient's body, there is a slight chance that this DNA could unintentionally be introduced into the patients reproductive cells. If this happens, it could produce changes that may be passed on if a patient has children after treatment.

One study to help find a vaccine for Covid-19 aims to use the principles behind gene therapy to get the vaccine ready. The researchers' method uses a harmless virus as a vector to bring DNA into the patient's cells. The DNA should then instruct the cells to make a coronavirus protein that would stimulate the immune system to fight off future infections.

While a mass-produced vaccine may still take a while, this study is one of at least 90 vaccine projects around the world trying to find a cure for Covid-19. However, some experts are worried that a vaccine may never be available. According to our previous report, Dr David Nabarro, a professor of global health at Imperial College London, who also serves as a special envoy to the WHO on Covid-19, said, "There are some viruses that we still do not have vaccines against."

See the rest here:
Can gene therapy help develop coronavirus vaccine? Researchers banking on this technology for breakthrough - MEAWW

Recommendation and review posted by Bethany Smith

Veteran Bollywood actor Rishi Kapoor, who was battling leukemia for the last two years, died at Mumbais Sir HN Reliance Foundation Hospital on Thursday (April 30) morning. He was 67. Rishi Kapoor got treated for leukemia in the US for a year and had returned to India in September 2019.

Leukemia is a blood cancer caused by a rise in the number of white blood cells in your body. Those white blood cells crowd out the red blood cells and platelets that your body needs to be healthy. The extra white blood cells dont work right. A cancer of blood-forming tissues, hindering the body's ability to fight infection.

Dr Rahul Bhargava, Director, Haematology, Haemato Oncology and Bone Marrow Transplant, Fortis Memorial Research Institute, Gurugram says:

Leukemia, often fatal, is a blood cancer. As with cancer, it is associated with an exponential rise in the number of white blood cells. Symptoms begin to manifest slowly and can often be mistaken for something else sweating uncontrollably, shaking, fever, vomiting. It is caused by huge was is reduced focus on ones own health.

Intake of processed food, soda, artificial and synthetic sweets and preservatives, pesticide use in farms, lack of physical exercise, excessive tobacco and drug consumption, excessive alcohol intake, caffeine consumption are the main culprits causing cancer. Family history also plays an important role in a leukemia diagnosis. Only through screening can it be identified and if caught early managed. One needs to be mindful and ensure that they are employing good lifestyle habits.

This means eating green leafy vegetables and fruits, going for a 30 minutes walk every day or engaging in any other form of exercise for 30 minutes a day, drinking adequate amount of water to keep flushing out the toxins, controlling or completely eliminating our use of tobacco and other unnatural substances. Processed food and sugars should be consumed in control, they are the single largest cause of mutation to cells.

Leukemia symptoms vary, depending on the type of leukemia. Common leukemia signs and symptoms include:

Leukemia can also cause symptoms in organs that have been infiltrated or affected by the cancer cells. For example, if the cancer spreads to the central nervous system, it can cause headaches, nausea and vomiting, confusion, loss of muscle control, and seizures.

Leukemia can also spread to other parts of your body, including:

The major types of leukemia are:

Blood has three types of cells: white blood cells that fight infection, red blood cells that carry oxygen, and platelets that help blood clot. Every day, your bone marrow makes billions of new blood cells, and most of them are red cells. When you have leukemia, your body makes more white cells than it needs. These leukemia cells cant fight infection the way normal white blood cells do. And because there are so many of them, they start to affect the way your organs work. Over time, you may not have enough red blood cells to supply oxygen, enough platelets to clot your blood, or enough normal white blood cells to fight infection.

Leukemia is usually treated by a hematologist-oncologist. These are doctors who specialize in blood disorders and cancer. The treatment depends on the type and stage of the cancer. Some forms of leukemia grow slowly and don't need immediate treatment. However, treatment for leukemia usually involves one or more of the following:

Source: Information has been taken from various health website

Read more| National Honesty Day 2020: Date, history, significance and quotes on the value of honesty

More:
What Is Leukemia? Here's all you need to know - India Today

Recommendation and review posted by Bethany Smith

Global Cell Therapy Technologies Market was valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample//31531/

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Cell Therapy Technologies Market: Overview

Cell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying//31531/

Global Cell Therapy Technologies Market: Drivers and Restraints

The growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation Analysis

On the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional Analysis

North America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at: https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

View original post here:
Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2019-2026) - MR Invasion

Recommendation and review posted by Bethany Smith